13Th World Congress of Biological Psychiatry 18 – 22 June 2017 Copenhagen, Denmark Bella Center Copenhagen

INVITATION PROGRAMME Call for Abstracts / Scientifi c Programme

WFSBP Congress 2017 13th World Congress of Biological Psychiatry 18 – 22 June 2017 Copenhagen, Denmark Bella Center Copenhagen

www.wfsbp-congress.org

Organised by: World Federation of Societies of Biological Psychiatry

Hosted by the Danish Society of Biological Psychiatry WFSBP 2017 Table of Contents

Page

3 Invitation to the 13th World Congress of Biological Psychiatry

4 About WFSBP

5 About the WFSBP Congress 2017 Congress Administration WFSBP Executive Committee International Scientific Programme Committee Honorary Committee (HC) National Presidents Chairs of the Local Organising Committee (LOC) Congress Ambassadors

Congress Programme 7 Colour Legend 8 Preliminary Scientific Programme Schedule 13 Preliminary Scientific Programme 39 Topics 41 Call for Abstracts for Free Communications and Posters 42 Format Descriptions of the Scientific Sessions 43 WFSBP Awards 44 Congress Information 45 General Information

WFSBP GLOBAL HEADQUARTERS CONGRESS AND EXHIBITION OFFICE Zum Ehrenhain 34

22885 Barsbüttel, Germany Phone: +49 – 40 – 670 882 90 Fax: +49 – 40 – 670 328 82 91 Phone: +49 – 30 – 300 669-0 Email: [email protected] Email: [email protected] www.wfsbp-congress.org

CONGRESS VENUE Bella Center Copenhagen Center Boulevard 5 2300 Copenhagen S, Denmark www.bellacentercopenhagen.dk

2 WFSBP 2017 Invitation to the 13th World Congress of Biological Psychiatry

Dear Colleagues,

It is both an honor and a privilege to welcome all of you to the 13th World Congress of Biolog- ical Psychiatry in Copenhagen, 18 – 22 June 2017, which will be an excellent setting to discuss the current progress in molecular biology, the development of novel drugs based upon new concepts, and the advances in modern neuroscience that will change our approach to psychiatric disorders and our attitudes towards mental health care. It is the time for biological psychiatry to be developed into the new stage where biopsycho-socio-spiritual aspects are integrated for the betterment of patients and families with mental and psychiatric disorders. The field of Masatoshi Takeda biological psychiatry is expanding by the development of bioinformatics (genomics, transcrip- tomics, proteomics) identifying importance of glycome, lipidome, metabolome, and desea- some, and brain activity mapping methodology. Looking back a few examples of previous world congress of biological psychiatry in Paris (2009), Prague (2011), Kyoto (2013), and Athens (2015), it is remarkable to have witnessed significant contribution of biological psychiatry research into the diagnosis, treatment, care, and even prevention of psychiatric and mental disorders. The field of biological psychiatry is rapidly developing, reaching the new stage of clinical application. Genetic engineering, iPS cells, brain mapping, and other new technologies have been integrated into the translational research in the field. Modified electroconvulsive therapy (mECT), repetitive trans-cranial stimulation (rTMS), near-infrared spectroscopy (NIRS), and de- Constantin R. Soldatos coded neurofeedback (DecNef) are examples of recent application in biological psychiatry. Considering the impact of most CNS disorders, biological psychiatry is expected to fill in the unmet need for CNS drugs including new generation antipsychotics, anti-depressants, anti- epileptics, anxiolytics, and sleep inducers, and others. Biological psychiatry is the field where academia and industry should proceed together aiming for the developing of new methods of diagnosis and treatment of CNS disorders. We are confident that the 13th World Congress of Biological Psychiatry in Copenhagen will be the superb setting for presentation and discussion of recent findings in biological psychiatry. To this end, 5 Lectures, 3 Debates, 12 Task Force Symposia / Workshops and 83 independent Sym- posia / Workshops are already forming the core scientific programme; all of them on very inter- esting topics to be presented by prominent researchers-scientists in their respective fields. Gregers Wegener We trust that the breadth of topics our congress is tackling, will encourage many more colleagues around the world to submit their recent findings, through our Free Communication and Poster presentation sessions. For more information regarding relevant deadlines, please visit our congress website. We are looking forward to meeting you in Copenhagen and interacting with you both socially and professionally.

With our best wishes

Prof. Masatoshi Takeda Prof. Constantin R. Soldatos Prof. Gregers Wegener Congress President Chair of the International Chair of the Local Scientific Programme Organising Committee Committee

3 WFSBP 2017 About WFSBP

Founded in 1974 in Buenos Aires, Argentina, the World The principle objectives of WFSBP are: Federation of Societies of Biological Psychiatry is a aa To foster and encourage scientific research and ad- non-profit world wide organization composed of 63 Na- vancement in the field of Biological Psychiatry tional Societies of Biological Psychiatry and Individual aaTo improve the quality of training spanning all the bio- Members representing professionals from over 70 coun- logical psychiatry sciences tries. aaTo promote education and achieve the highest level of knowledge and understanding within the field With this multitude of countries represented in its world- aaTo provide information and guidance to all institutions, wide community, the World Federation has built an inter- societies or individuals with an interest in biological national network of over 4,500 opinion leaders, the ma- psychiatry jority of which are key opinion-leaders in the practice of aaTo establish, build, and maintain solid collaboration Biological Psychiatry. with international and national organisations related to biological psychiatry WFSBP members by continent Educational activities, regional, international and world n n 3,7 % 0,5 % congresses, the interactive website www.wfsbp.org, and n 6,6 % The World Journal of Biological Psychiatry build the World Federation’s portfolio and insure its worldwide influence. n 7,1 % The development of worldwide treatment guidelines is one of WFSBP’s main areas of international leadership.

Year after year, more and more professionals choose to join the World Federation’s Biological Psychiatry arena and enjoy its exclusive educational and networking opportunities. In the coming years WFSBP is looking forward to welcoming over 15 new eminent member societies from different parts of the world.

n 24,5 % n 57,6 % WFSBP members by field of activity:

As of December 2015 n Clinicians 88 % n Researchers 12 %

n Europe n Africa n Asia n North America n South America n Oceania

4 WFSBP 2017 About the WFSBP Congress 2017

CONGRESS ADMINISTRATION The 13th World Congress of Biological Psychiatry will be organised by the World Federation of Societies of Biological Psychiatry (WFSBP)

WFSBP EXECUTIVE COMMITTEE Members of ISPC A. H. Glassman, USA President (2015 – 2019) G. Alexopoulos, USA* B. Glenthoj, Denmark Masatoshi Takeda, Japan C. A. Altamura, Italy* G. M. Goodwin, UK C. Arango, Spain D. Gorelick, USA Vice President (2013 – 2017) E. Baca Garcia, Spain P. Gorwood, France* Tudor Udristoiu, Romania M. Bauer, Germany* A. Grace, USA* E. Belfort, Venezuela H. Grunze, UK* Past President (2015 – 2017) A. Benyamina, France G. Hajak, Germany Constantin R. Soldatos, Greece M. Berk, Australia* A. Halaris, USA* J. Bobes, Spain A. Hasan, Germany Secretary (2013 – 2017) A. Bozkurt, Cyprus S. Heckers, USA Lakshmi N. Yatham, Canada N. Boutros, USA C. Hiemke, Germany C. L. Bowden, USA E. Hollander, USA Treasurer (2013 – 2017) P. Boyer, France E. Holsboer-Trachsler, Switzerland* Martin Hatzinger, Switzerland J. Bradford, Canada W. G. Honer, Canada P. Brambilla, Italy J. Horacek, Czech Republic Vice Secretary (2013 – 2017) M. Bras, Croatia A. Jablensky, Australia Ladislav Hosak, M. S. Buchsbaum, USA R. Kahn, The Netherlands Czech Republic A. Burns, UK J. Kane, USA R. Castilla-Puentes, USA* S. Kanba, Japan* Vice Treasurer (2013 – 2017) D. Castle, Australia* T. Kato, Japan Victoria Valdez, Ecuador E. Ceskova, Czech Republic* C. Katona, UK M. Cetkovich-Bakmas, Argentina W. Kaye, USA INTERNATIONAL SCIENTIFIC Y. Hwa Chou, Taiwan* J. Kennedy, Canada* PROGRAMME COMMITTEE (ISPC) H. Correa, Brazil* L. Konopka, USA Chair P. Cosyns, Belgium H. R. Kranzler, USA* Constantin R. Soldatos, Greece P. Courtet, France* C. Krieg, Germany B. Dean, Australia* T. Kudo, Japan Vice Chairs J. de Buitelaar, The Netherlands J. Soo Kwon, Korea Peter Falkai, Germany M. Dierick, Belgium S. Lamy, France Lakshmi Yatham, Canada B. Dubois, France R. Lanzenberger, Austria* K. Fountoulakis, Greece* V. Larach, Chile Deputy Chairs S. Frangou, UK M. Leboyer, France Dimitris Dikeos, Greece W. Gaebel, Germany M.S. Lee, Korea* Yoshio Hirayasu, Japan F. D. Garcia, Brazil* M. Lejoyeux, France Tudor Udristoiu, Romania W. F. Gattaz, Brazil B. Leonard, Ireland* P. Gejman, USA Y. Levkovitz, Israel Secretary A. Germanavicious, Lithuania A. Lopez Mato, Argentina* Georgios Kiosterakis, Greece M. George, USA* C. Lyketsos, USA

* Special correspondents of ISC Core Group 5 WFSBP 2017 About the WFSBP Congress 2017

R. McCarley, USA L. Siever, USA NATIONAL PRESIDENTS P. Mc Gorry, Australia D. St. Clair, UK A. Corrales, Argentina P. Mc Guire, UK N. Stefanis, Greece* A. Boyajyan, Armenia M. Maes, Belgium* J. Steiner, Germany C. Geretsegger, Austria A. Malafosse, Switzerland T. Suhara, Japan S. Claes, Belgium J.-L. Martinot, France M. Taleb, France/Algeria N. D. Noya-Tapia, Bolivia V. Matei, Romania* T. Taneli, USA A. Kucukalic, Bosnia-Herzegovina H. Mayberg, USA J. Tellez-Vargas, Colombia A. Marcolin, Brazil H. Y. Meltzer, USA J. Treasure, UK O. Atanasova Mikova-Demireva, A. Meyer-Lindenberg, Germany N. A. Uranova, Russia Bulgaria A. Kant Mital, India P. Udomratn, Thailand* R. W. Lam, Canada E. Mohan Das, India I. Udristoiu, Romania* E. Olea, Chile N. Müller, Germany W. van den Brink, The Netherlands* C. Gutierrez, Columbia T. Murai, Japan* J. van Os, The Netherlands R. Castro, Costa Rica Z. Nahas, Lebanon D. Velakoulis, Australia* M. Jakovljevic, Croatia D. Nutt, UK N. Venizelos, Sweden* L. Hosak, Czech Republic J. Ospina-Duque, Colombia* E. Vieta, Spain* G. Wegener, Denmark N. Ozaki, Japan J. Waddington, Ireland F. Solis de Mendez, Dominican C. Pantelis, Australia* A. Weinstein Israel Republic G. Papadimitriou, Greece P. Whybrow, USA M. Meneses-Guevara, Ecuador T. Paparrigopoulos, Greece* X. Yu, China A. Okasha, Egypt G. Parker, Australia M. Zanarini, USA M. Meija Pena, El Salvador L. Pezewas, Austria Y. Zervas, Greece* J. Harro, Estonia O. Pogarell, Gemany J. Zohar, Israel P. Courtet, France S. G. Potkin, USA S. Herpertz, Germany R. Post, USA* HONORARY COMMITTEE (HC) C. R. Soldatos, Greece M. Rapaport, USA Jules Angst, Switzerland H. Soto Chavez, Guatemala M.S. Reddy, India* Jose Luis Ayuso, Spain M. Aguilar Lopez, Honduras E. Richelson, USA Jorge Ciprian-Ollivier, Argentina S.-W. Tang, Hong Kong P. Riederer, Germany Jorge Alberto Costa e Silva, Brazil C. Banki, Hungary D. Rujescu, Germany Tetsuo Fukuda, Japan R. Nagpal, India R. Rupprecht, Germany Gerardo Heinze, Mexico A. J. Tanra, Indonesia J. Rybakowski, Poland Carlos Roberto Hojaij, Brazil D. Gothelf, Israel H. Sackeim, USA Florian Holsboer, Germany M. Maj, Italy T. Saito, Japan Siegfried Kasper, Austria T. Nishikawa, Japan P. Salgado Pineda, Spain Jeffrey Lieberman, USA M. Assimov, Kazakhstan M. Sarchiapone, Italy Julien Mendlewicz, Belgium C. Uk Lee, Korea T. Schlaepfer, Germany* Hans-Jürgen Möller, Germany B. Kupca, Latvia A. Schmitt, Germany Robin Murray, UK C. Baddoura, Libanon L. Schneider, USA Ahmed Okasha, Egypt J. Neveranskas, Lithnania C. Schulz, USA Mitsumoto Sato, Japan B. Stefanovski, Macedonia T. G. Schulze, Germany* Norman Sartorius, Switzerland S. Krishnaswamy, Malaysia S. Seedat, South Africa* Göran Sedvall, Sweden D. Moussaoui, Morocco E. Seifritz, Switzerland Costas Stefanis, Greece G. Villanueva Colin, Mexico A. Serretti, Italy* Florence Thibaut, France H. Lovdahl, Norway E. Serfaty, Argentina Michael Trimble, UK M. Amin, Pakistan W. W. Shen, Taiwan G. Da Costa, Panama

* Special correspondents of ISC Core Group 6 WFSBP 2017 About the WFSBP Congress 2017 / Colour Legend

L. Villalba, Paraguay Members of LOC CONGRESS AMBASSADORS E. Galli, Peru Kjeld Andersen, Denmark Carlo Altamura, Italy A. Wichniak, Poland Ole A. Andreassen, Norway Ajit Avasthi, India J. Relvas, Portugal Lone Baandrup, Denmark Charles Baddoura, Libanon T. Udristoiu, Romania Per Bech, Denmark Robert Belmaker, Israel S. Mosolov, Russia Nils Bilenberg, Denmark Enrique Galli, Peru N. Maric Bojovic, Serbia Bjørn Ebdrup, Denmark Peter Gaszner, Hungary L. Vavrusova, Slovakia Jesper Ekelund, Finland Bai Han, China S. Seedat, South Africa Anders Fink-Jensen, Denmark Gerhard Heinze, Mexico M. Bernardo, Spain Birte Glenthøj, Denmark Nick Kates, Canada M. Ramklint, Sweden Simon Glerup, Denmark Donatella Marazziti, Italy M. Hatzinger, Switzerland Jaanus Harro, Estonia Giorgio Racagni, Italy Ch.-Y. Liu, Taiwan Torsten Bjørn Jacobsen, Denmark M.S. Reddy, India P. Udomratn, Thailand Martin Balslev Jørgensen, Denmark Pedro Ruiz, USA B. Taneli, Turkey Olli Kampman, Finland Janusz Rybakowski, Poland A. V. Kalueff, Ukraine Lars Kessing, Denmark Dan Stein, South Africa G. Bouza, Uruguay Gitte Moos Knudsen, Denmark Andi J. Tanra, Indonesia J. Ibáñez-Domínguez, Venezuela Rasmus Licht, Denmark Si Tian-Mei, China Pall Mathiasson, Iceland Eduard Vieta,Spain CHAIRS OF THE LOCAL Tanja Michel, Denmark Shigeto Yamawaki, Japan ORGANISING COMMITTEE (LOC) Thomas Middelboe, Denmark Yukio Yoneda, Japan Chair Ole Mors, Denmark Allan Young, UK Gregers Wegener, Denmark Merete Nordentoft, Denmark Kerstin Plessen, Denmark Deputy Chairs Andreas Reif, Germany Ida Hageman, Denmark Dan Rujescu, Germany Søren Dinesen Østergaard, Denmark Bo Söderpalm, Sweden Per Hove Thomsen, Denmark Jari Tiihonen, Sweden Anders Tingström, Sweden Poul Videbech, Denmark Thomas Werge, Denmark

COLOUR CODES OF SESSIONS (PRELIMINARY SCIENTIFIC PROGRAMME, PAGES 8 – 38)

OP Opening Lecture TFS Task Force Symposia WS Workshops

PL Plenary Lectures TFW Task Force Workshops FC Free Communications

D Debates S Symposia SA Satellite Symposia

7 WFSBP 2017

Preliminary Scientific Programme Schedule / Sunday, 18 June 2017

8:30 S-01 S-02 S-03 WS-01 Towards novel Psychiatric services Dissecting the role Initiatives from the rapid-acting antide- in emergency of the neurotrophin Spanish Society of 9:00 pressants departments: Brain Derived Neu- Biological Psychia- Challenges and rotrophic Factor in try: From evidence Free Communications solutions cocaine addiction: to experience Clues from clinical 9:30 and preclinical studies

10:00

S-04 S-05 S-06 WS-02 Pathways of Extracellular vesi- Drug addiction and New investigations neuroprogression cles in neuropsy- GPCR heterore- on the relationship 10:30 in Bipolar Disorder chiatric diseases: ceptor complexes: between working (BP) Basic mechanisms What goes wrong memory and and biomarkers in receptor plas- ADHD ticity as addiction Free Communications 11:00 develops?

11:30

12:00

12:30 S-07 S-08 Social cognition Inflammation and neuronal cor- markers of 13:00 relates in patients peripherial blood with schizophrenia in depression Satellite Symposia Free Communications spectrum 13:30

14:00

14:30 S-09 S-10 S-11 S-12 Mechanisms Effects and side ef- Abnormal neu- New approaches contributing to fects of electrocon- rogenesis in schizo- into diagnosis 15:00 neuroprogression vulsive therapy phrenia and treatment of in psychiatric disor- psychotic Bipolar Free Communications ders and promising Disorder (BP) interventions 15:30

16:00

16:30 S-13 Biomarkers for early diagnosis 17:00 of Alzheimer's Disease (AD) and Satellite Symposia Free Communications other neurodegenerating diseases: 17:30 Advantages and limitations

18:00 Opening Ceremony 18:00 – 19:00 18:30 (incl. OP-01 The microbiome-gut-brain axis: A key regulator of brain & behaviour across the lifespan)

Registration Counter 07:30 – 19:00

8 WFSBP 2017

Monday, 19 June 2017 / Preliminary Scientific Programme Schedule

8:30 S-14 S-15 S-16 S-17 S-18 S-19 S-20 Problematic Posttraumatic The elephant in Psychosis is Epigenetic Psychedelics: Affective and sexual behav- Stress Disorder the room: The disrespectful modification, Mechanisms psychotic iors: Diagnostic, (PTSD) and role of glial cells to diagnostic effect of early and applications psychopa- 9:00 categorical, gender in psychiatric boundaries: life stress, and in psychiatry thology from Free Com- epidemiological, disorders Nosological and signaling pregnancy to munications imaging, psy- pathobiological mechanisms in early adulthood: 9:30 chopathological implications suicide The dynamic and treatment of psychoses developmental considerations beyond ... interplay ... 10:00

Plenary Lecture 10:30 PL-01 Drug discovery in neuroscience: Promises, barriers and opportunities

11:00 D-01 TFS-01 S-21 S-22 S-23 WS-03 S-24 Antidepressants Therapeutic Measurement- Dissecting the Combining Current status Serotonin and 11:30 are effective drug monitoring, based psychia- shared and non- cognitive re- of electrocon- anxiety disor- for treating pharmaco- try: Toward shared biolog- mediation with vulsive therapy ders: Recent acute bipolar genetics and rating scale- ical features in brain imaging in the treatment evidences from Free Com- 12:00 depression brain imaging based assess- schizophrenia techniques: Evi- of major neuroimaging munications methods as tools ments in the and autism dence for neu- psychiatric studies for optimizing real world spectrum ral changes or disorders pharmacothera- disorder neuroplasticity? 12:30 py in psychiatry

13:00

13:30

Satellite Symposia 14:00

14:30

15:00 S-25 TFS-02 TFW-01 S-26 S-27 WS-04 S-28 tDCS: From Post-mortem Workshop of Into novel Beyond unitary Rethinking Wake and sleep research to findings across the WFSBP drugs for models of depression in electroenceph- clinical practice psychiatric dis- Task Force on depression psychosis: the Century alogramm pro- 15:30 orders and their Genetics: Focus Confronting XXI: Where vide biomarkers Free Com- association on pharmaco- complex are we now of depression munications with cognitive genomics etiology and in biological 16:00 symptoms dimensionality psychiatry?

16:30

17:00 S-29 TFS-03 Autism spec- Update trum disorders biomarkers in 17:30 in adults – from psychiatry the clinical Satellite Symposia Free Com- phenotype to munications the underlying 18:00 neurobiology – novell technics such ... 18:30

Registration Counter Poster Exhibition Technical Exhibition 08:00 – 18:30 09:00 – 17:00 09:00 – 17:00

9 WFSBP 2017

Preliminary Scientific Programme Schedule / Tuesday, 20 June 2017

8:30 S-30 S-31 S-32 S-33 S-34 WS-05 S-35 Recent insights Duration of New per- Epigenetic Sex hormones Gesture as New insights in- in schizophrenia untreated spectives on biomarkers for and their window to to the neurobiol- physiopathology psychosis: From transcranial the diagnosis of wide-ranging psychosis ogy and treat- 9:00 and treatments neuroimaging to magnetic mood disorders effects on psy- pathobiology: ment aspects of Free Com- clinical trials stimulation chopathology From aberrant obsessive communications in psychiatric body experience pulsive disorder 9:30 disorders to social inter- comorbid with action schizophrenia and bipolar ... 10:00

Plenary Lecture 10:30 PL-02 Novel treatments in mood disorders: Molecular mechanisms and clinical applications

11:00 D-02 TFS-04 S-36 S-37 S-38 WS-06 The Research Sleep in The role of Neurobiologic Treatment resis- Neurobiology 11:30 Domain Criteria depression and the nucleus imaging tant schizophre- of suicidal (RDoC) can cognition – from accumbens in studies of mood nia: Definitions, behaviour create a new research to clini- psychiatry disorders, neu- psychobiology Free Communications 12:00 kind of taxono- cal practice rogenetics and and clinical my holding antidepressant treatment greater promise action with posi- compared to the tron emission 12:30 traditional ... tomography

13:00

13:30

Satellite Symposia 14:00

14:30

15:00 WS-07 TFS-05 TFW-02 S-39 S-40 WS-08 S-41 Merging Biomarkers WFSBP Con- Current research Alzheimer's Functional neu- Electroconvul- evidence and for schizo- sensus on the on the use of Disease (AD) roanatomy of sive therapy clinical practice phrenia: From management cannabinoids pathophysiolo- hallucinations for depression 15:30 in management molecules to of agitation in gy, prevention – optimising Free Com- of depression: brain function. psychiatry and treatment treatment and munications The CANMAT A consensus of strategies: maintaining 16:00 experience the WFSBP Task Where we stand recovery Force on biolo- and where we gical markers go? 16:30

17:00 S-42 TFS-06 Neuroepigenetic Electroconvul- approaches to sive therapy: 17:30 assess disease Beyond depres- risk, mechanism sion Satellite Symposia Free Com- and treatment munications

18:00

18:30

Registration Counter Poster Exhibition Technical Exhibition 08:00 – 18:30 09:00 – 17:00 09:00 – 17:00

10 WFSBP 2017

Wednesday, 20 June 2017 / Preliminary Scientific Programme Schedule

8:30 S-43 S-44 S-45 S-46 S-47 Novel ap- Cannabinoid Behavioral Neurobiology Catecolamines, proaches in Receptor (CBR) Addictions: and psycho- anhedonia and 9:00 mechanisms gene variations Diagnosis, pharmacology depression of action of in neuropsy- co-morbidity of aggressive be- Free Communications antidepressant chiatric dis- and neuro- haviour: Where treatment orders biology are we? 9:30

10:00

Plenary Lecture 10:30 PL-03 Epigenetic consequences of early adversity: Implications for psychiatric disorders

11:00 D-03 TFS-07 S-48 S-49 S-50 WS-09 Deep brain Enhancing the Pharmacoge- Evidence-based Real time Schizophrenia 11:30 stimulation is role of primary netics of drug guidelines for assessment of research in a worthwhile care in looking defense and treatment of psychopatholo- Chile treatment after people neuroprotec- major depres- gy and behavior Free Communications 12:00 method in with mental tion: From the sive disorder: in Bipolar Dis- psychiatry health problems: Neandertal to Contrasting order (BP) using A new position the modern views across the e-mental health paper from the humans world technologies 12:30 Collaborative ...

13:00

13:30

Satellite Symposia 14:00

14:30

15:00 S-51 TFS-08 TFW-03 S-52 S-53 WS-10 Advances in Men's mental WFSBP Treat- The G protein Suicidal Evidence for biomarker health: Contem- ment Guideline coupled recep- behavior: brain stimula- 15:30 development porary aspects Session: Do tors as a target Neurobiological tion methods in for neurostimu- bipolar mixed for psychotropic and genetic schizophrenia Free Communications lation states merit drugs determinants a treatment 16:00 guideline on its own?

16:30

17:00 S-54 TFS-09 S-55 Lithium as a Providing acute Rediscovering neuroprotective inpatient care Lithium 17:30 agent: When for children, and how? adolescents and Satellite Symposia Free Com- young adults munications from a men‘s 18:00 mental health perspective: Focus on ... 18:30

Registration Counter Poster Exhibition Technical Exhibition 08:00 – 18:30 09:00 – 17:00 09:00 – 17:00

11 WFSBP 2017

Preliminary Scientific Programme Schedule / Thursday, 22 June 2017

8:30 S-56 S-57 S-58 S-59 S-60 S-61 Clinical effects Causes and Novel thera- The relevance of Multi-omics and Suicide: Aspects and neural consequences of peutics for neu- Neuregulin1- psychiatry: The that burn 9:00 mechanisms inflammation in rodegenerative ErbB4 signaling missing molecu- of electro- Bipolar Disorder disorders for neuropsychi- lar link Free Communications convulsive (BP) atric patho- therapy in major mechanisms: 9:30 depression and Converging schizophrenia insights from mouse ... 10:00

Plenary Lecture 10:30 PL-04 Lithium in mood disorders including a homage to Danish contribution

11:00 S-62 S-63 S-64 S-65 S-66 S-67 Innovative Atypical neu- Operational- Cell-type spe- NMDA receptor Spectrum of approaches in rotransmitters in izing the cific epigenetic, antagonists in Mood Disorders 11:30 suicide research psychiatry: Rele- dysconnection proteomic and psychiatry (MD): Where vance for future syndrome: gene expression is the place for Free Communications therapeutics Translational ap- signatures in mixed states? proaches reveal schizophrenia: 12:00 brain network New findings dysfunction in from post-mor- schizophrenia tem ... 12:30

13:00

13:30 Satellite Symposia

14:00

14:30

15:00 S-68 S-69 S-70 S-71 S-72 S73 Dynamical Increased intes- Current use Sex-specific Socio-demo- Neuropatholo- brain: How tinal permeabili- of EEG-based neuroendo- graphic and gic implication 15:30 brain complexity and bacterial techniques in crinological clinical differ- of abnormal ty changes with translocation in psychiatry findings in ences between cortico-basal Free Communications aging and neuro-psychia- conduct Bipolar I and II ganglia connec- mental illness? tric disorders disorder Disorder (BP) tivity in schizo- 16:00 and implications phrenia hallu- for treatment cination and its models 16:30

Closing Ceremony 17:00

17:30

18:00

18:30

Registration Counter Poster Exhibition 08:00 – 17:30 09:00 – 17:00

12 SUN MON TUE WED THU WFSBP 2017

Opening Lecture, Plenary Lectures, Debates / Preliminary Scientific Programme

Opening Lecture Debates aaSunday, 18 June 2017 aaMonday, 19 June 2017

OP-01 D-01 18:00 – 19:00 11:15 – 12:45 The microbiome-gut-brain axis: A key regulator of Antidepressants are effective for treating acute bipolar brain & behaviour across the lifespan depression Chair: Masatoshi Takeda, Japan Chair: Lakshmi Yatham, Canada Speaker: John F. Cryan, Ireland Proponent: Glenda MacQueen, Canada Opponent: Robert Post, USA

Plenary Lectures aaTuesday, 20 June 2017 aa Monday, 19 June 2017 D-02 11:15 – 12:45 PL-01 The Research Domain Criteria (RDoC) can create 10:15 – 11:00 a new kind of taxonomy holding greater promise Drug discovery in neuroscience: Promises, barriers and compared to the traditional Nosological Classification opportunities Systems in psychiatry Chair: Lakshmi Yatham, Canada Chair: Sabine Herpertz, Germany Speaker: Husseini Manji, USA Proponent: Andreas Heinz, German Opponent: Henning Saß, Germany aaTuesday, 20 June 2017 aaWednesday, 21 June 2017 PL-02 10:15 – 11:00 D-03 Novel treatments in mood disorders: Molecular 11:15 – 12:45 mechanisms and clinical applications Deep brain stimulation is a worthwhile treatment Chair: Gregers Wegener, Denmark method in psychiatry Speaker: Carlos Zarate, USA Chair: Gregers Wegener, Denmark Proponent: Thomas Schläpfer, Germany aaWednesday, 21 June 2017 Opponent: Marwan Hariz, United Kingdom

PL-03 10:15 – 11:00 Epigenetic consequences of early adversity: Implications for psychiatric disorders Chair: Constantin R. Soldatos, Greece Speaker: Elisabeth Binder, Germany aaThursday, 22 June 2017

PL-04 10:15 – 11:00 Lithium in mood disorders including a homage to Danish contribution Chair: Tudor Udristoiu, Romania Speaker: Janusz Rybakowski, Poland

13 WFSBP 2017 MON TUE

Preliminary Scientific Programme /WFSBP Task Force Symposia

WFSBP Task Force Symposia TFS-02-004 Different changes in cortical muscarinic receptors in aaMonday, 19 June 2017 psychiatric and neurological disorders Brian Dean, Australia T51: PSYCHOPHARMACOLOGY

TFS-01 T22: MOLECULAR NEUROBIOLOGY 11:15 – 12:45 TFS-03 Therapeutic drug monitoring, pharmacogenetics 17:00 – 18:30 and brain imaging methods as tools for optimizing pharmacotherapy in psychiatry Update biomarkers in psychiatry Chair: Chin B. Eap, Switzerland Chair: Peter Riederer, Germany Co-Chair: Christoph Hiemke, Germany Co-Chair: Peter Falkai, Germany

TFS-01-001 TFS-03-001 Pharmacogenetics in psychiatry Biomarkers for schizophrenia Chin B. Eap, Switzerland Florence Thibaut, France TFS-01-002 TFS-03- 002 Therapeutic drug monitoring in psychiatry Biological marker in alcoholism Christoph Hiemke, Germany Toshikazu Saito, Japan TFS-01-003 TFS-03-003 Brain imaging in psychiatry Specifity of biomarkers for OCD / ADHD Gerhard Gründer, Germany Edna Grünblatt, Switzerland TFS-01-004 TFS-03-004 Strategies for the implementation of genetic biomarkers Specifity of biomarkers for anxiety in clinical practice Borwin Bandelow, Germany Daniel Müller, Canada aaTuesday, 20 June 2017 T24: NEUROPATHOLOGY T45: SLEEP DISORDERS: BASIC / CLINICAL TFS-02 TFS-04 15:00 – 16:30 11:15 – 12:45 Post-mortem findings across psychiatric disorders and Sleep in depression and cognition – from research to their association with cognitive symptoms clinical practice Chair: Andrea Schmitt, Germany Chair: Edith Holsboer-Trachsler, Switzerlan Co-Chair: Johann Steiner, Germany Co-Chair: Birendra N. Mallick, India

TFS-02-001 TFS-04-001 Alterations in hippocampal oligodendrocyte and neuron Sleep as biomarker: Predictor of emotional regulation number in patients with schizophrenia, Bipolar Disorder and depression (BP) and major depression Martin Hatzinger, Switzerland Peter Falkai, Germany TFS-04-002 TFS-02-002 Sleep in dementia: A biomarker of cognition? GABAergic system impairment in the hippocampus Dimitris Dikeos, Greece and superior temporal gyrus of patients with paranoid schizophrenia TFS-04-003 Johann Steiner, Germany Sleep and synaptic dysfunction in depression Anne Eckert, Switzerland TFS-02-003 Presynaptic contributions to cognitive reserve TFS-04-004 William Honer, Canada REM sleep and prevention of neurodegeneration: Role of noradrenaline Birendra N. Mallick, India

14 TUE WED WFSBP 2017

WFSBP Task Force Symposia / Preliminary Scientific Programme

T43: SCHIZOPHRENIA: BASIC / CLINICAL aaWednesday, 21 June 2017 TFS-05 T20: LIAISON PSYCHIATRY 15:00 – 16:30 TFS-07 Biomarkers for schizophrenia: From molecules to brain 11:15 – 12:45 function. A consensus of the WFSBP Task Force on Enhancing the role of primary care in looking after biological markers people with mental health problems: A new position Chair: Andrea Schmitt, Germany paper from the Collaborative Care Task Force of the Co-Chair: Daniel Martins de Souza, Brazil WFSBP TFS-05-001 Chair: Nick Kates, Canada Genetic biomarkers TFS-07-001 Dan Rujescu, Germany Improving primary mental health care – Definitions, TFS-05-002 models, principles and challenges Neuroimaging biomarkers Nick Kates, Canada Nikolaos Koutsouleris, Germany TFS-07-002 TFS-05-003 Integrating mental health services within primary care Molecular biomarkers settings Daniel Martins de Souza, Brazil Henrikje Klasen, The Netherlands TFS-05-004 TFS-07-003 Cognition biomarkers The role of the family physician in delivering mental Peter Falkai, Germany health care Torleif Ruud, Norway T47: STIMULATION METHODS (ECT, TMS, VNS, DBS) TFS-07-004 TFS-06 Capacity building, training and adapting the approach for different countries 17:00 – 18:30 Nick Kates, Canada Electroconvulsive therapy: Beyond depression Chair: Georgios Petrides, USA T51: MEN'S MENTAL HEALTH Co-Chair: William McDonald, USA TFS-08 TFS-06-001 15:00 – 16:30 ECT for the treatment of catatonia Tom Bolwig, Denmark Men's mental health: Contemporary aspects Chair: Leo Sher, USA TFS-06-002 Co-Chair: Timothy Rice, USA ECT in autism spectrum disorders: Catatonia and beyond TFS-08-001 Lee Wachtel, USA Future research and clinical directions in the field of TFS-06-003 men's mental health ECT for agitation in elderly patients with dementia Leo Sher, USA Adriana Hermida, USA TFS-08-002 TFS-06-004 Towards a neuropsychiatric model of disruptive behav- ECT-related mortality rates ior disorders in boys and young men: Developmental Søren Dinesen Østergaard, Denmark deficits in the emotion regulation system, their origin, and their therapeutic address Timothy Rice, USA TFS-08-003 Sex differences in addictive disorder and its clinical connotation Shih-Ku Lin, Taiwan

15 WFSBP 2017 MON TUE WED

Preliminary Scientific Programme /WFSBP Task Force Symposia and Workshops

TFS-08-004 TFW-01-003 Sex differences in early predictors of adult personality Whole exom sequencing reveals risk factors in treat- and intelligence ment resistant depression Trine Flensborg-Madsen, Denmark Alessandro Serretti, Italy TFW-01-004 T50: VIOLENCE: BASIC / CLINICAL Pharmacogenetic discoveries and applications in psychiatric populations TFS-09 Jim Kennedy, Canada 17:00 – 18:30 Providing acute inpatient care for children, adolescents and young adults from a men's mental aaTuesday, 20 June 2017 health perspective: Focus on violence reduction T13: EMERGENCY PSYCHIATRY Chair: Pilar Trelles, USA TFW-02 Co-Chair: Lesha Shah, USA 15:00 – 16:30 TFS-09-001 WFSBP consensus on the management of agitation in Brain development: A focus on normal male develop- psychiatry ment and psychopathology Chair: Siegfried Kasper, Austria Pilar Trelles, USA Co-Chair: Eduard Vieta, Spain TFS-09-002 TFW-02-001 Asking for the IM: What to do when the disruptive male Agitation: Causes and differential diagnosis child appears to seek punishment Marina Garriga, Spain Timothy Rice, USA TFW-02-002 TFS-09-003 Agitation in schizophrenia Agression in adolescence Dieter Naber, Germany Lesha Shah, USA TFW-02-003 TFS-09-004 Agitation in Bipolar Disorder (BP) Violent and suicidal behavior among young male veter- Lakshmi Yatham, Canada ans on an inpatient psychiatric unit Leo Sher, USA TFW-02-004 WFSBP Consensus on agitation in psychiatry Eduard Vieta, Spain WFSBP Task Force Workshops aaWednesday, 21 June 2017 aaMonday, 19 June 2017 T6: BIPOLAR DISORDERS: BASIC / CLINICAL T32: PHARMACOGENETICS TFW-03 TFW-01 15:00 – 16:30 15:00 – 16:30 WFSBP Treatment Guideline Session: Do bipolar mixed Workshop of the WFSBP Task Force on genetics: Focus states merit a treatment guideline on its own? on pharmacogenomics Chair: Siegfried Kasper, Austria Chair: Dan Rujescu, Germany Co-Chair: Heinz Grunze, United Kingdom Co-Chair: Jim Kennedy, Canada TFW-03-001 TFW-01-001 Clinical manifestations of bipolar mixed states-epidemi- Pharmacogenetics in schizophrenia ological and clinical research Rainald Mössner, Germany Jean-Michel Azorin, France TFW-01-002 TFW-03-002 Largest genome wide association study on agranulocyto- The changing concept of mixed states over time: DSM5 sis under Clozapine broadening and downgrading at the same time Dan Rujescu, Germany Eduard Vieta, Spain

16 WED SUN WFSBP 2017

WFSBP Task Force Workshops, Symposia / Preliminary Scientific Programme

TFW-03-003 S-02-003 The WFSBP Treatment guideline for mixed states- Depression and medical comorbidity in emergency evidence and recommendations departments in Mexico Heinz Grunze, United Kingdom Ricardo Secin, Mexico TFW-03-004 S-02-004 What the CINP guideline recommends in mixed states Self-inflicted injuri in children and adolescents: A study Konstantinos Fountoulakis, Greece in a tertiary care hospital in Santiago de Chile Arturo Grau, Chile

Symposia T1: ADDICTIVE DISORDERS aaSunday, 18 June 2017 S-03 08:30 – 10:00 T2: ANTIDEPRESSANTS: BASIC / CLINICAL Dissecting the role of the neurotrophin Brain Derived S-01 Neurotrophic Factor in cocaine addiction: Clues from 08:30 – 10:00 clinical and preclinical studies Towards novel rapid-acting antidepressants Chair: Fabio Fumagalli, Italy Chair: Tomi Rantamäki, Finland S-03-001 Co-Chair: Gregers Wegener, Denmark Acute exposure to cocaine during brain development S-01-001 evokes depressive-like behaviors via downregulation of Rapid acting antidepressants in chronic pain Brain Derived Neurotrophic Factor signaling Ipek Yalcin, France Fabio Fumagalli, Italy S-01-002 S-03-002 Morphological and structural alterations following rapid Cocaine and orbitofrontal cortical Brain Derived acting antidepressants Neurotrophic Factor deficiency induce habit-based Gregers Wegener, Denmark decision-making: Blockade by trkB stimulation Shannon Gourley, USA S-01-003 Antidepressant potential of cannabidiol: Preclinical S-03-003 evidence Systemic administration of the brain-penetrant TrkB Sâmia Joca, Brazil antagonist cyclotraxin-b reduces short and long access cocaine intake S-01-004 Michel Verheij, The Netherlands Anesthetics as rapid-acting antidepressants Tomi Rantamäki, Finland S-03-004 Brain Derived Neurotrophic Factor and cocaine in clinical samples: A useful biomarker for treatment? T20: LIAISON PSYCHIATRY Lisia von Diemen, Brazil S-02 08:30 – 10:00 T6: BIPOLAR DISORDERS: BASIC / CLINICAL Psychiatric services in emergency departments: S-04 Challenges and solutions 10:15 – 11:45 Chair: Ruby Castilla-Puentes, USA Co-Chair: Tatiana Falcone, USA Pathways of neuroprogression in Bipolar Disorder (BP) Chair: Benicio Frey, Canada S-02-001 Co-Chair: Flavio Kapczinski, Brazil Psychiatric consultations in rural general hospitals – Latinos vs. Anglos S-04-001 Bernardo Ng, USA Indicators or risk and resilience in the high-risk offspring of bipolar parents S-02-002 Anne Duffy, Canada A study of insomnia and cormobid psychiatric condi- tions in rehabilitation clinics Franklin Escobar, Colombia

17 WFSBP 2017 SUN

Preliminary Scientific Programme /Symposia

S-04-002 T22: MOLECULAR NEUROBIOLOGY Lithium compared to quetiapine in the maintenance S-06 phase after a first episode of mania Michael Berk, Australia 10:15 – 11:45 Drug addiction and GPCR heteroreceptor complexes: S-04-003 What goes wrong in receptor plasticity as addiction Biological rhythms and illness progression in Bipolar develops? Disorder (BP) Chair: Kjell Fuxe, Sweden Benicio Frey, Canada Co-Chair: Anita Hansson, Germany S-04-004 Illness trajectories and neuroprogression in Bipolar S-06-001 Disorder (BP) Neurochemical mechanisms underlying goal-directed Flavio Kapczinski, Brazil and habitual drug seeking and how these mechanisms produce compulsions: Focus on Gq-coupled glutamate receptors T22: MOLECULAR NEUROBIOLOGY Peter Kalivas, USA S-05 S-06-002 10:15 – 11:45 Homo and heteroreceptor complexes participate in Extracellular vesicles in neuropsychiatric diseases: learning and memory and as an emerging target for Basic mechanisms and biomarkers treatment of cocaine addiction Chair: Takashi Kudo, Japan Dasiel Borroto-Escuela, Sweden Co-Chair: Dimitrios Kapogiannis, USA S-06-003 S-05-001 Evidence for a role of A2A-D2 heteroreceptor complexes Extracellular vesicles as a source of biomarkers for in cocaine addiction Alzheimer's Disease Malgorzata Filip, Poland Dimitrios Kapogiannis, USA S-06-004 S-05-002 Dopamine D4 –MOR interactions prevent nigrostriatal Tau inside neutrally-derived exosome dopamine pathway activation by morphine: Relevance Dominic Walsh, USA for drug addiction Alicia Rivera, Spain S-05-003 Mechanisms of exosome involvement in neurodegerative diseases T43: SCHIZOPHRENIA: BASIC / CLINICAL Andrew Hill, Australia S-07 S-05-004 12:30 – 14:00 Changes in exosomes proteins by the degree of stress Social cognition and neuronal correlates in patients Takashi Kudo, Japan with schizophrenia Chair: Gabriele Sachs, Austria Co-Chair: Armida Mucci, Italy

S-07-001 Neurocognitive predictors of social cognition Vijaya Lakshmi Valaparla, India S-07-002 Emotional intelligence in patients suffering from schizophrenia and unaffected siblings Alex Hofer, Austria S-07-003 Social cognition and negative symptoms in schizophrenia: Constructs, assessment and relationships with functional outcome Armida Mucci, Italy

18 SUN WFSBP 2017

Symposia / Preliminary Scientific Programme

S-07-004 S-09-004 Neurobiological correlates of the treatment of emotion Promising neuroprotective and anti-inflammatory inter- processing in schizophrenia ventions to arrest neuroprogression Gabriele Sachs, Austria Angelos Halaris, USA

T19: INFLAMMATION PSYCHIATRY T47: STIMULATION METHODS (ECT, TMS, VNS, DBS) S-08 S-10 12:30 – 14:00 14:30 – 16:00 Inflammation markers of peripherial blood in Effects and side effects of electroconvulsive therapy depression spectrum Chair: Michael Grözinger, Germany Chair: Piotr Galecki, Poland Co-Chair: Helge Frieling, Germany Co-Chair: Angelos Halaris, USA S-10-001 S-08-001 Effects of ECT on the oxygen saturation in the frontal brain (Auto)immune biomarkers of depression and subtypes Michael Grözinger, Germany Michael Maes, Thailand S-10-002 S-08-002 DNA methylation of P11/S100A10: A putative marker of Targeting inflammation to prevent depression response to ECT? Michael Berk, Australia Helge Frieling, Germany S-08-003 S-10-003 Stratification of depressed patients by means of Electroconvulsive therapy enhances amyloid ß 1-42 in blood markers of inflammation, growth factors and the cerebrospinal fluid of patients with major depression kynurenine metabolites Alexander Sartorius, Germany Angelos Halaris, USA S-10-004 S-08-004 The EFFECT-Dep Trial (ISRCTN23577151): Immediate Omega-3 fatty acids, inflammation and depression: and long-term cognitive outcomes From biological mechanisms to clinical application Declan McLoughlin, Ireland Kuan-Pin Su, Taiwan T43: SCHIZOPHRENIA: BASIC / CLINICAL T39: PSYCHONEUROIMMUNOLOGY S-11 S-09 14:30 – 16:00 14:30 – 16:00 Abnormal neurogenesis in schizophrenia Mechanisms contributing to neuroprogression in Chair: Dragos Inta, Germany psychiatric disorders and promising interventions Co-Chair: Guo-Li Ming, USA Chair: Angelos Halaris, USA S-11-001 S-09-001 Modeling predisposition to schizophrenia using hiPSCs Inflammatory and innate immune markers of neuropro- Kristen Brennand, USA gression in depressed and teenage suicide brain S-11-002 Ghanshyam Pandey, USA Neurogenesis and psychiatric neurodevelopmental S-09-002 disorders Major depression as a prelude to dementia: What is the Guo-Li Ming, USA evidence? S-11-003 Brian Leonard, Ireland Precise activation of the Reelin pathway controls den- S-09-003 dritic maturation, synapse formation and glial ensheath- Neuroimaging of microglia activation in major depression ment of adult-generated granule cells Jeffrey Meyer, Canada Eduardo Soriano, Spain

19 WFSBP 2017 SUN MON

Preliminary Scientific Programme /Symposia

S-11-004 S-13-004 Adult neurogenesis in the striatum: Effect of psychiatric Current diagnostic approaches in frontotemporal lobar treatment degeneration Dragos Inta, Germany Markus Otto, Germany

T6: BIPOLAR DISORDERS: BASIC / CLINICAL aaMonday, 19 June 2017 S-12 T1: ADDICTIVE DISORDERS 14:30 – 16:00 S-14 New approaches into diagnosis and treatment of 08:30 – 10:00 psychotic Bipolar Disorder (BP) Problematic sexual behaviors: Diagnostic, categorical, Chair: Carlo Altamura, Italy epidemiological, imaging, psychopathological and Co-Chair: Allan Young, United Kingdom treatment considerations S-12-001 Chair: Marc Potenza, USA Neuroimaging aspects of psychotic Bipolar Disorder Co-Chair: Florence Thibaut, France (BP) Paolo Brambilla, Italy S-14-001 Classification and clinical issues relating to hypersexuality S-12-002 Marc Potenza, USA Candidate biomarkers for psychotic Bipolar Disorder S. Kraus (BP): The role of neuroinflammation and hormones Massimiliano Buoli, Italy S-14-002 Sexual impulsivity, psychopathology and trauma: Gen- S-12-003 der-related differences Pharmacological treatment of psychotic Bipolar Disorder Galit Erez, Israel (BP) Trisha Suppes, USA S-14-003 Advances in pharmacological treatments for sex offenders Florence Thibaut, France T10: DEMENTIA: BASIC / CLINICAL S-14-004 S-13 SYMPOSIUM Neurobiology of compulsive sexual behaviors 16:30 – 18:00 Valerie Voon, United Kingdom Biomarkers for early diagnosis of Alzheimer's Disease (AD) and other neurodegenerating diseases: T35: POSTTRAUMATIC STRESS: BASIC / CLINICAL Advantages and limitations Chair: Piotr Lewczuk, Germany S-15 Co-Chair: Henrik Zetterberg, Sweden 08:30 – 10:00 Posttraumatic Stress Disorder (PTSD) and gender S-13-001 Chair: Hans-Jürgen Möller, German New developments in the biomarkers for Alzheimer's Co-Chair: Victoria Valdez, Ecuador Disease (AD) Kaj Blennow, Sweden S-15-001 S-13-002 Clinical issues: PTSD and gender violence Amyloid beta 42/40 Ratio in diagnosis of AD: Do we Victoria Valdez, Ecuador need it? S-15-002 Piotr Lewczuk, Germany Course and prognosis PTSD S-13-003 Kayihan Oguz Karamustafa, Turkey Sensitive technologies for blood biomarkers in neurode- S-15-003 generation Biological aspects and PTSD Henrik Zetterberg, Sweden Soraya Seedat, South Africa S-15-004 Genetics and PTSD Sian Hermann, South Africa

20 MON WFSBP 2017

Symposia / Preliminary Scientific Programme

T43: SCHIZOPHRENIA: BASIC / CLINICAL S-17-004 Post-stroke psychosis: Pathobiology and behavioral S-16 susceptibility 08:30 – 10:00 Eileen Joyce, United Kingdom The elephant in the room: The role of glial cells in psychiatric disorders T49: SUICIDE: BASIC / CLINICAL Chair: Sabina Berretta, USA Co-Chair: Mikhail Pletnikov, USA S-18 08:30 – 10:00 S-16-001 Epigenetic modification, effect of early life stress, and Psychiatric genetic risk factors in healthy and diseased signaling mechanisms in suicide astrocytes Chair: Ghanshyam Pandey, USA Mikhail Pletnikov, USA Co-Chair: Victoria Arango, USA S-16-002 Glia-extracellular matrix interactions in the pathophysi- S-18-001 ology of schizophrenia and Bipolar Disorder (BD) Impact of the early-life environment on the epigenetic Sabina Berretta, USA regulation of the anterior cingulate gyrus Gustavo Turecki, Canada S-16-003 Abnormalities of glutamate transporter localization in S-18-002 severe mental illness Expression and methylation of glucocorticoid receptors Robert McCullumsmith, USA and FKBP5 in teenage and adult suicide Ghanshyam Pandey, USA S-16-004 Evidence for neuroinflammation, gliosis and leaky brain S-18-003 in people with schizophrenia Genome-wide epigenetic changes in suicide attempters Cyndi Shannon Weickert, Australia Jussi Jokinen, Sweden S-18-004 T43: SCHIZOPHRENIA: BASIC / CLINICAL 5-HT1A receptor anti-apoptotic transduction pathways in suicide S-17 Victoria Arango, USA 08:30 – 10:00 Psychosis is disrespectful to diagnostic boundaries: T11: DEPRESSION: BASIC / CLINICAL Nosological and pathobiological implications of psychoses beyond the schizophrenia spectrum S-19 Chair: John Waddington, Ireland 08:30 – 10:00 Co-Chair: Peter Buckley, USA Psychedelics: Mechanisms and applications in psychiatry S-17-001 Chair: Tomas Palenicek, Czech Republic Reconciling the diversity of psychotic illness and dimen- Co-Chair: Franz X. Vollenweider, Switzerland sional concepts with current diagnostic algorithms Rajiv Tandon, USA S-19-001 S-17-002 Role of 5-HT2A receptors in the mechanism of action Psychosis in major depressive disorder: Systematic com- of psilocybin and LSD and the treatment of affective parisons with and beyond the schizophrenia spectrum disorders John Waddington, Ireland Franz X. Vollenweider, Switzerland S-17-003 S-19-002 Psychosis in Bipolar Disorder (BP): Genetics and rela- The effect of psilocybin on brain connectivity and emo- tionships to paternal age tional processing in healthy volunteers Peter Buckley, USA Tomas Palenicek, Czech Republic J. Waddington S-19-003 Psilocybin for the treatment of depression Robin Carhart-Harris, United Kingdom

21 WFSBP 2017 MON

Preliminary Scientific Programme /Symposia

S-19-004 S-21-003 Exploring the therapeutic potential of ayahuasca in the The role for measurement-based care for bipolar disor- treatment of psychiatric disorders der in current and future clinical practice Jordi Riba, Spain Eduard Vieta, Spain S-21-004 T7: CHILDHOOD & ADOLESCENT DISORDERS: PANSS-6: A new rating scale for both research and clini- BASIC / CLINICAL cal care in schizophrenia S-20 Søren Dinesen Østergaard, Denmark 08:30 – 10:00 Affective and psychotic psychopathology from T43: SCHIZOPHRENIA: BASIC / CLINICAL pregnancy to early adulthood: The dynamic S-22 developmental interplay between genes, structures and 11:15 – 12:45 functions Dissecting the shared and non-shared biological Chair: Paolo Brambilla, Italy features in schizophrenia and autism spectrum Co-Chair: Michael Kaess, Germany disorder S-20-001 Chair: Kenji Tsuchiya, Japan Can personality and parental care impact on brain Co-Chair: Manabu Makinodan, Japan developmen? S-22-001 Paolo Brambilla, Italy Comparative genetic analysis of autism spectrum disorder S-20-002 and schizophrenia: Focus on rare variants Neurodevelopmental trajaectories and psychopathology Branko Aleksic, Japan in adolescents and adults who were born very preterm S-22-002 Chiara Nosarti, United Kingdom The genetic overlap between autism and schizophrenia: S-20-003 Focus on common variation Grin2b mediates susceptibility to affective problems in Jakob Grove, Denmark children and adolescents S-22-003 Maria Nobile, Italy Neurobiological findings in schizophrenia and autism S-20-004 spectrum disorder Corollary discharge auditory hallucinations and schizo- Ryota Hashimoto, Japan phrenia: A structural network analysis S-22-004 Romy Hemze, Germany Neural-immune mechanisms in development and disease Allison Bialas, USA T11: DEPRESSION: BASIC / CLINICAL S-21 T9: COGNITIVE NEUROSCIENCE 11:15 – 12:45 S-23 Measurement-based psychiatry: Toward rating scale- 11:15 – 12:45 based assessments in the real world Combining cognitive remediation with brain Chair: Christoph U. Correll, USA imaging techniques: Evidence for neural changes or Co-Chair: Søren Dinesen Østergaard, Denmark neuroplasticity? S-21-001 Chair: Martin Lepage, Canada Measurement-based care psychiatry: Where are we at Co-Chair: Kamilla Miskowiak, Denmark and where should we head? S-23-001 Andrew A. Nierenberg, USA Neural markers and predictors of therapeutic change S-21-002 with cognitive enhancement therapy Measurement-based care versus standard care for major Matcheri Keshavan, USA depression: Conducting a success randomized controlled trial with blind raters Christoph U. Correll, USA

22 MON WFSBP 2017

Symposia / Preliminary Scientific Programme

S-23-002 S-25-003 Short-term working memory training for individuals Effects of tDCS on biological reactivity to stress and with psychosis: Cognitive and neurophysiological effects decision making Christopher Bowie, Canada Jerome Brunelin, France S-23-003 S-25-004 Randomised trial of low support cognitive training for TDCS in mood disorders – ready to clinical practice? schizophrenia: Cortical and behavioural outcomes Results from recent phase-III randomised, controlled Gary Donohoe, Ireland trials S-23-004 Andre Brunoni, Brazil SESAME: A brief intervention for memory in schizophrenia. Behavioral and imaging data T33: PHARMACOLOGY Martin Lepage, Canada S-26 15:00 – 16:30 T4: ANXIETY DISORDERS: BASIC/CLINICAL Into novel drugs for depression S-24 Chair: Erich Seifritz, Switzerland 11:15 – 12:45 S-26-001 Serotonin and anxiety disorders: Recent evidences Conceptual strategies of Big Pharma into innovation in from neuroimaging studies psychiatric therapies: Future leads Chair: Eduard Maron, Estonia Siegfried Kasper, Austria Co-Chair: Tomas Furmark, Sweden S-26-002 S-24-001 Personalizing psychiatry treatment Serotonin system and panic disorder Florian Holsboer, Germany Eduard Maron, Estonia S-26-003 S-24-002 Psychedelic drugs and clinical markers as innovation Serotonin system and social anxiety disorder road to psychopharmacotherapy Tomas Furmark, Sweden Franz X. Vollenweider, Switzerland S-24-003 S-26-004 Serotonin system and obsessive-compulsive disorder GHB as a candidate drug for stratified depression Oliver Pogarell, Germany suptypes S-24-004 Oliver G. Bosch, Switzerland Serotonin regulation of anxiety neuronal network Andreas Frick, Sweden T43: SCHIZOPHRENIA: BASIC / CLINICAL S-27 T47: STIMULATION METHODS (ECT, TMS, VNS, DBS) 15:00 – 16:30 S-25 Beyond unitary models of psychosis: Confronting 15:00 – 16:30 complex etiology and dimensionality tDCS: From research to clinical practice Chair: Mikhail Pletnikov, USA Chair: Emmanuel Poulet, France Co-Chair: John Waddington, Ireland Co-Chair: Jerome Brunelin, France S-27-001 S-25-001 Recognising the dimensionality of psychotic illness: Translational research on tDCS: Data from a German Broadening the phenotype to the affective domain multisite project Catherine Belzung, France Frank Padberg, Germany S-27-002 S-25-002 Addressing the translational challenge of etiological Combining tDCS with neuroimaging diversity: Complex gene-environment interactions in Shirley Fecteau, Canada risk for psychosis Mikhail Pletnikov, USA

23 WFSBP 2017 MON TUE

Preliminary Scientific Programme /Symposia

S-27-003 T7: CHILDHOOD & ADOLESCENT DISORDERS: Closing the translational gap between heritability and BASIC / CLINICAL genetics: Complex gene-gene interactions in risk for S-29 psychosis 17:00 – 18:30 John Waddington, Ireland Autism spectrum disorders in adults – from the clinical S-27-004 phenotype to the underlying neurobiology – novell Extending the strategy for translation: Human induced technics such as phenotype-based genetic variants pluripotent stem cells association studies, high field magnet resonance Kristen Brennand, USA imaging and 3d brain organoids Chair: Tanja Michel, Denmark T11: DEPRESSION: BASIC / CLINICAL Co-Chair: Sophia Frangou, USA

S-28 S-29-001 15:00 – 16:30 On the outcome, time course and clinical presentation Wake and sleep electroencephalogramm provide of autism in adults: A longitudinal study of clinical biomarkers of depression trajectories Chair: Axel Steiger, Germany Marlene Briciet Lauritsen, Denmark Co-Chair: Thorsten Mikoteit, Switzerland S-29-002 S-28-001 Modulation of the autistic phenotypes in the broader Central and autonomous nervous system activity in the fragile X gene family by accumulated common gene prediction of antidepressant treatment variants Sebastian Olbrich, Switzerland Hannelore Ehrenreich, Germany S-28-002 S-29-003 The value of prefrontal theta cordance of resting EEG in New insights from proteomics and nanotechnology- the prediction of antidepressant response 3 D brain organoids: A promising new tool for an vitro Martin Brunovsky, Czech Republic model for ASD Tanja Michel, Denmark S-28-003 Novel REM-sleep derived biomarkers of depression S-29-004 Thorsten Mikoteit, Switzerland The role of myelination in neurodevelopmental disorders Sophia Frangou, USA S-28-004 sLORETA derived from REM sleep EEG as biomarkers for treatment response in depression after antidepressant aaTuesday, 20 June 2017 medication T43: SCHIZOPHRENIA: BASIC / CLINICAL Marcel Pawlowski, Germany S-30 08:30 – 10:00 Recent insights in schizophrenia physiopathology and treatments Chair: Pierre-Michel Llorca, France Co-Chair: Guillaume Fond, France

S-30-001 Bridging the gap between research and clinical practice: The development of a national network of schizophrenia expert centers Guillaume Fond, France S-30-002 Schizophrenia pathophysiology: Recent insights from neuroimaging on glutamatergic and neuroinflammatory mechanisms Oliver Howes, United Kingdom

24 TUE WFSBP 2017

Symposia / Preliminary Scientific Programme

S-30-003 S-32-003 The influence of hormones on schizophrenia Neurophysiological correlates of various transcranial Iris Sommer, The Netherlands magnetic stimulation paradigms in patients with psychi- S-30-004 atric disorders: In search of novel biomarkers Novel adjunctive therapy approaches for inflammatory Yoshihiro Noda, Japan disturbances in psychiatric disorders S-32-004 Michael Berk, Australia Combination of computerized cognitive remediation and transcranial magnetic stimulation T43: SCHIZOPHRENIA: BASIC/CLINICAL Akihiro Takamiya, Japan S-31 T11: DEPRESSION: BASIC/CLINICAL 08:30 – 10:00 Duration of untreated psychosis: From neuroimaging S-33 to clinical trials 08:30 – 10:00 Chair: John Kane, USA Epigenetic biomarkers for the diagnosis of mood Co-Chair: Erika Jaaskelainen, Finland disorders Chair: Tetsuro Ohmori, Japan S-31-001 Co-Chair: Lourdes Fañanás, Spain Is DUP a moderator of effectiveness with comprehen- sive specialty care in first episode schizophrenia? S-33-001 John Kane, USA DNA methylation profiles of the Brain-derived Neu- S-31-002 rotrophic Factor (BDNF) gene as a potent diagnostic The impact of DUP on short and long term outcomes in biomarker in major depression schizophrenia Manabu Fuchikami, Japan Erika Jaaskelainen, Finland S-33-002 S-31-003 Antenatal prediction of postpartum depression with Is there a relationship between DUP and brain structure? blood DNA methylation biomarkers Aristotle Voineskos, Canada Zachary Kaminsky, USA S-31-004 S-33-003 MRI resting state functional connectivity and DUP Blood diagnostic biomarkers for major depressive disor- Deepak Sarpal, USA der using multiplex DNA methylation profiles Shusuke Numata, Japan

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS) S-33-004 Differential methylation and variable methylation in de- S-32 pression: A genome-wide analysis of monozygotic twins 08:30 – 10:00 Aldo Cordova-Palomera, Spain New perspectives on transcranial magnetic stimulation in psychiatric disorders T40: PSYCHOPATHOLOGY Chair: Shinsuke Kito, Japan Co-Chair: Motoaki Nakamura, Japan S-34 08:30 – 10:00 S-32-001 Sex hormones and their wide-ranging effects on Transcranial magnetic stimulation in the treatment of psychopathology bipolar depression Chair: Andrea Gogos, Australia Shinsuke Kito, Japan Co-Chair: Mark Geyer, USA S-32-002 Clinical and neurobiological effects of Quadripulse S-34-001 Stimulation (QPS) and Theta Burst Stimulation (TBS) in Estrogen, raloxifene and schizophrenia Mood Disorders (MD) Cyndi Shannon Weickert, Australia Motoaki Nakamura, Japan

25 WFSBP 2017 TUE

Preliminary Scientific Programme /Symposia

S-34-002 S-36-002 Cortical gene expression changes underlying estrogen's The role of nucleus accumbens in social cognition effect in schizophrenia Leonhard Schilbach, Germany Andrea Gogos, Australia S-36-003 S-34-003 The role of nucleus accumbens in impulsivity 17b-estradiol effects on psychosis-like attentional Valerie Voon, United Kingdom abnormalities in rats S-36-004 Ina Weiner, Israel Deep brain stimulation of the nucleus accumbens S-34-004 Sina Kohl, Germany Sex differences in depression: The role of neuroestrogens Christina Dalla, Greece T11: DEPRESSION: BASIC / CLINICAL S-37 T27: OBSESSIVE-COMPULSIVE DISORDERS: BASIC / CLINICAL 11:15 – 12:45 Neurobiologic imaging studies of mood disorders, S-35 neurogenetics and antidepressant action with positron 08:30 – 10:00 emission tomography New insights into the neurobiology and treatment Chair: J. John Mann, USA aspects of obsessive compulsive disorder comorbid Co-Chair: Gitte Moos Knudsen, Denmark with schizophrenia and bipolar affective disorder Chair: E. Mohandas, India S-37-001 Co-Chair: Narayan R. Mutalik, India Familial transmission of 5-HT1A autoreceptor up-regulation: An impaired serotonnergic endophenotype in S-35-001 mood disorders Neurobiology of obsessive compulsive disorder comor- J. John Mann, USA bid with schizophrenia S-37-002 Narayan R. Mutalik, India Molecular neuroimaging and genetics S-35-002 Gitte Moos Knudsen, Denmark Evidence based management of obsessive compulsive S-37-003 disorder comorbid with schizophrenia cAMP Cascade in major depressive disorder: Downreg- Firoz Kazhungil, India ulation in unmedicated patients and normalization with S-35-003 treatment Neurobiology of obsessive compulsive disorder comor- Robert Innis, USA bid with bipolar disorder S-37-004 Rajan Nishanth Jayarajan, Australia Predictiveness of peripheral and clinical markers for PET S-35-004 measurement of inflammation and monoamine oxidase: Recent updates in the management of obsessive com- Implications for biomarker development pulsive disorder comorbid with Bipolar Disorder (BP) Jeffrey Meyer, Canada Pawan Sharma, Nepal T43: SCHIZOPHRENIA: BASIC / CLINICAL T9: COGNITIVE NEUROSCIENCE S-38 S-36 SYMPOSIUM 11:15 – 12:45 11:15 – 12:45 Treatment resistant schizophrenia: Definitions, The role of the nucleus accumbens in psychiatry psychobiology and clinical treatment Chair: Jens Kuhn, Germany Chair: John Kane, USA Co-Chair: Leonhard Schilbach, Germany Co-Chair: Ofer Agid, Canada

S-36-001 S-38-001 The anatomy of the nucleus accumbens Methodological issues in clinical trial designs for TRS Ioannis Mavridis, Greece John Kane, USA

26 TUE WFSBP 2017

Symposia / Preliminary Scientific Programme

S-38-002 S-40-003 A longitudinal perspective on the evolution of treatment Alzheimer drug discovery: Targeting synaptic glutamate resistance signaling Ofer Agid, Canada Markku Kurkinen, USA S-38-003 S-40-004 The biology of treatment resistance Nanotechnology for early detection and treatment of Oliver Howes, United Kingdom Alzheimer's Disease (AD): Where we stand and where S-38-004 we go? Definitions and epidemiology of treatment resistance Jerzy Leszek, Poland Christoph U. Correll, USA T47: STIMULATION METHODS (ECT, TMS, VNS, DBS) T1: ADDICTIVE DISORDERS S-41 S-39 15:00 – 16:30 15:00 – 16:30 Electroconvulsive therapy for depression – optimising Current research on the use of cannabinoids treatment and maintaining recovery Chair: Aviv Weinstein, Israel Chair: Declan McLoughlin, Ireland Co-Chair: Amine Benyamina, France Co-Chair: Pascal Sienaert, Belgium

S-39-001 S-41-001 Cannabis use disorder and its effects on cognitive function The KEEP-WELL Trial: Ketamine for depression relapse Valerie Curran, United Kingdom prevention following ECT (NCT02414932) Declan McLoughlin, Ireland S-39-002 The relationship between cannabis and psychosis S-41-002 Deepak Cyril D´Souza, USA Immediate and long-term outcomes for Brief-pulse (BP) vs Ultrabrief-pulse (UBP) high-dose unilateral ECT: The S-39-003 ResPECT trials’ experience The genetics of cannabis use disorder Pascal Sienaert, Belgium Amine Benyamina, France H.-P. Spaans, E. Verwijk, F. Bouckaert S-39-004 S-41-003 The effects of chronic use of synthetic cannabinoids on Pre- and post-ECT cognitive performance as predictors executive brain function for outcome and relapse in depression (NTR1304) Aviv Weinstein, Israel Esmée Verwijk, The Netherlands S-41-004 T10: DEMENTIA: BASIC / CLINICAL The PRIDE Trial – Prolonging remission in depressed S-40 elderly (NCT01028508): Results from the randomised 15:00 – 16:30 phase Charles Kellner, USA Alzheimer's Disease (AD) pathophysiology, prevention and treatment strategies: Where we stand and where we go? T22: MOLECULAR NEUROBIOLOGY Chair: Jerzy Leszek, Poland S-42 Co-Chair: Ramon Cacabelos, Spain 17:00 – 18:30 S-40-001 Neuroepigenetic approaches to assess disease risk, Pharmacogenetics of cerebrovascular phenotypes of risk mechanism and treatment in dementia Chair: Alfonso Buil, Denmark Ramon Cacabelos, Spain Co-Chair: Jonathan Mill, United Kingdom

S-40-002 S-42-001 Insulin resistance in neurodegeneration: The role of CACNA1C hypermethylation associated with Bipolar p53/miRNA/SIRT1 axis Disorder (BD) Kazimierz Gasiorowski, Poland Anna Starnawska, Denmark D. Demontis, A. Pen, A. Hedemand, A. L. Nielsen,

27 WFSBP 2017 TUE WED

Preliminary Scientific Programme /Symposia

N. H. Staunstrup, J. Grove, T. D. Als, A. Jarram, T17: GENETICS N. L. O’Brien, O. Mors, A. McQuillin, A. D. Børglum S-44 S-42-002 08:30 – 10:00 Epigenomic trajectories across human brain develop- Cannabinoid Receptor (CBR) gene variations in ment: Relevance for schizophrenia and other neurode- neuropsychiatric disorders velopmental disorders Chair: Hiroki Ishiguro, Japan Jonathan Mill, United Kingdom Co-Chair: Emmanuel Onaivi, USA S-42-003 Neonatal epigenetic profiling in Danish twins discor- S-44-001 dant for psychiatric disorder Environmental stressors induce psychosis based on Shantel Weinsheimer, Denmark genetic variation of CB2Rs C. Hansen, A. Starnawska, T. Sparsø, W. Mazin, Hiroki Ishiguro, Japan M. Bertalan, J. Grauholm, M. Bækvad-Hansen, A. Buil, S-44-002 D. M. Hougaard, T. M. Werge ECB system alteration in an animal model of autism S-42-004 spectrum disorders Epigenetics in schizophrenia and association with anti- Eugene Dennis, USA psychotic response to clozapine S-44-003 Marta Bosia, Italy Species differences in CBR genes Qing-Rong Liu, USA aaWednesday, 21 June 2017 S-44-004 T2: ANTIDEPRESSANTS: BASIC / CLINICAL CBR genetics: From mice to human subjects Emmanuel Onaivi, USA S-43 08:30 – 10:00 T1: ADDICTIVE DISORDERS Novel approaches in mechanisms of action of antidepressant treatment S-45 Chair: Rainer Rupprecht, Germany 08:30 – 10:00 Behavioral addictions: Diagnosis, co-morbidity and S-43-001 neurobiology Signal transduction in membranes as mechanism of Chair: Michel Lejoyeux, France action of antidepressants Co-Chair: Aviv Weinstein, Israel Mark Rasenick, USA S-45-001 S-43-002 Internet gaming disorder- addiction, co-morbidity and Cytoskeleton as target for antidepressants the brain Massimiliano Bianchi, Ireland Aviv Weinstein, Israel S-43-003 S-45-002 Biomarkers during antidepressant treatment Neuroimaging evidence for considering hypersexuality Thomas Baghai, Germany as an addiction S-43-004 Florence Thibaut, France Relevance of P-Glycoprotein and blood brain barrier for S-45-003 antidepressant treatment New data on phenomenology and psychiatric comor- Carmine Pariante, United Kingdom bidity of compulsive buying Michel Lejoyeux, France S-45-004 The genetic background of gambling behavior Zsolt Demetrovics, Hungary E. Kótyuk, A. Vereczkei, R. Urbán, A. Eisinger, A. Magi, G. Kökönyei, A. Veres-Székely, Á. Gyollai, K. Blum, M. Sasvári-Székely, C. Barta

28 WED WFSBP 2017

Symposia / Preliminary Scientific Programme

T50: VIOLENCE: BASIC / CLINICAL T32: PHARMACOGENETICS S-46 S-48 08:30 – 10:00 11:15 – 12:45 Neurobiology and psychopharmacology of aggressive Pharmacogenetics of drug defense and behaviour: Where are we? neuroprotection: From the Neandertal to the modern Chair: Stefano Comai, Italy humans Co-Chair: Gabriella Gobbi, Canada Chair: Julia Stingl, Germany Co-Chair: Magnus Ingelman-Sundberg, Sweden S-46-001 Neurobiology and biomarkers of aggression S-48-001 Stefano Comai, Italy The evolutionary aspect of trait biomarkers in drug S-46-002 metabolism and neuroprotection Clinical management of aggression in childhood and Magnus Ingelman-Sundberg, Sweden adolescence S-48-002 Florian D. Zepf, Australia Pharmacogenetic polymorphisms on behavioral and S-46-003 structural brain phenotypes uncovered by neuroimaging Drug abuse/dependence and aggressive behaviour data Gabriella Gobbi, Canada Roberto Viviani, Austria S-46-004 S-48-003 Epilepsy, antiepileptic drugs and aggression Prevention of drug toxicity to the brain: The vulnerable Martin J. Brodie, United Kingdom brain and ADRs of nervous system disorders Julia Stingl, Germany

T11: DEPRESSION: BASIC / CLINICAL S-48-004 Pharmacogenetic factors in neuroprotection during S-47 neurodevelopment 08:30 – 10:00 Karim Barakat, Germany Catecolamines, anhedonia and depression Chair: Jose Luis Ayuso, Spain T11: DEPRESSION: BASIC / CLINICAL Co-Chair: Victoria Valdez, Ecuador S-49 S-47-001 11:15 – 12:46 Catecholamines, reward circuits and depression Evidence-based guidelines for treatment of major Gregor Hasler, Switzerland depressive disorder: Contrasting views across the S-47-002 world Positive affects and depression Chair: Roumen Milev, Canada Jorge Tellez-Vargas, Colombia Co-Chair: Allan Young, United Kingdom

S-47-003 S-49-001 Anhedonia and suicide behavior A subequatorial view: The new RANZCP guidelines Maurizio Pompili, Italy Gin Malhi, Australia S-47-004 S-49-002 Exploring the role of proinflammatory cytokines in The evolution of the CANMAT guidelines anhedonia Raymond Lam, Canada Ruby Castilla-Puentes, USA S-49-003 The view from the UK: BAP guidelines for Mood Disor- ders (MD) Allan Young, United Kingdom S-49-004 Even the best guidelines don't work unless they are implemented Sagar Parikh, USA

29 WFSBP 2017 WED

Preliminary Scientific Programme /Symposia

T6: BIPOLAR DISORDERS: BASIC / CLINICAL S-51-004 Predicting remission of suicidal ideation following S-50 Magnetic Seizure Therapy (MST) in patients with treat- 11:15 – 12:45 ment-resistant depression Real time assessment of psychopathology and behavior Zafiris J. Daskalakis, Canada in Bipolar Disorder (BP) using e-mental health technologies T3: ANTIPSYCHOTICS: BASIC/CLINICAL Chair: Lars Kessing, Denmark Co-Chair: Michael Bauer, Germany S-52 15:00 – 16:30 S-50-001 The G protein coupled receptors as a target for Mood instability and Bipolar Disorder (BD): Deriv- psychotropic drugs ing useful biosignatures from multidimensional, time Chair: Andrzej Pilc, Polan stamped, streamed data Co-Chair: Jeffrey P. Conn, USA John Geddes, United Kingdom S-50-002 S-52-001 Smartphone based ambulatory assessment of early Positive allosteric modulators of GPCRs as a novel treat- warning signs in Bipolar Disorder (BP) ment for schizophrenia Michael Bauer, Germany Jeffrey P. Conn, USA S-50-003 S-52-002 Smartphones as objective electronic behavioral bio- The mGlu5 receptor imaging in schizophrenia and markers of illness activity in Bipolar Disorder (BP) depression Lars Kessing, Denmark Gregor Hasler, Switzerland S-50-004 S-52-003 Voice recognition as objective electronic behavioral The mGlu2/3 receptor as a novel therapeutic target for biomarkers of illness activity in Bipolar Disorder (BP) treatment-resistant depression Maria Fauerholt-Jepsen, Denmark Shigeyuki Chaki, Japan S-52-004 T47: STIMULATION METHODS (ECT, TMS, VNS, DBS) The allosteric modulation of group III mGlu receptors as target for antipsychotic or antidepressant drugs S-51 Andrzej Pilc, Poland 15:00 – 16:30 Advances in biomarker development for T49: SUICIDE: BASIC/CLINICAL neurostimulation Chair: Paul Croarkin, USA S-53 Co-Chair: Motoaki Nakamura, Japan 15:00 – 16:30 Suicidal behavior: Neurobiological and genetic S-51-001 determinants Stimulation-induced neuroplasticity of prefrontal cortex Chair: Yogesh Dwivedi, USA in adult autism spectrum disorder Motoaki Nakamura, Japan S-53-001 S-51-002 Epigenetic modifications in brain of suicide individ- Glutamatergic biomarker development for repetitive uals: Focus on global and site-specific changes in transcranial magnetic stimulation 5-hydroxymethylcytosine Paul Croarkin, USA Gustavo Turecki, Canada S-51-003 S-53-002 Neurocognitive effects of major depressive disorder and Genetics of intermediate phenotypes for suicidal neurostimulation therapies behavior: Focus on impulsivity and aggression Shawn McClintock, USA Dan Rujescu, Germany S-53-003 Toxoplasmagondii seropositivity and suicidal behavior Teodor Postalache, USA

30 WED THU WFSBP 2017

Symposia / Preliminary Scientific Programme

S-53-004 aaThursday, 22 June 2017 Non-coding RNAs: Novel epigenetic regulators in T47: STIMULATION METHODS (ECT, TMS, VNS, DBS) suicidal behavior Yogesh Dwivedi, USA S-56 08:30 – 10:00 T51: PSYCHOPHARMACOLOGY Clinical effects and neural mechanisms of electroconvulsive therapy in major depression and S-54 schizophrenia 17:00 – 18:30 Chair: Robert Christian Wolf, Germany Lithium as a neuroprotective agent: When and how? Co-Chair: Philipp Thomann, Germany Chair: Galila Agam, Israel Co-Chair: Changlian Zhu, People's Republic of China S-56-001 ECT in major depression and schizophrenia: Indications S-54-001 and clinical effects In vivo lithium-induced augments mitochondrial function, Dusan Hirjak, Germany reduces neuroinflammation and increases autophagy S-56-002 Galila Agam, Israel Effects of ECT on brain structure and function: Lessons S-54-002 from major depressive disorder Lithium as a novel approach to treat developing brain Robert Christian Wolf, Germany injury S-56-003 Changlian Zhu, China, People’s Republic of ECT-related effects on regional brain volume and struc- S-54-003 tural networks in patients with schizophrenia and major Hui Zhang, USA depressive disorder S-54-004 Philipp Thomann, Germany Francoise Croute, France S-56-004 Modulation of intrinsic network connectivity by ECT T23: MOOD STABILISERS: BASIC/CLINICAL in patients with schizophrenia and major depressive disorder S-55 Fabio Sambataro, Italy 17:00 – 18:30 Rediscovering Lithium T6: BIPOLAR DISORDERS: BASIC / CLINICAL Chair: David Taylor, United Kingdom Co-Chair: Jonathan Meyer, USA S-57 08:30 – 10:00 S-55-001 Causes and consequences of inflammation in Bipolar The evidence for Lithium's antisuicide properties and Disorder (BP) impact on mortality Chair: Lars Kessing, Denmark Jimmi Nielsen, Denmark Co-Chair: Flavio Kapczinski, Brazil S-55-002 The evidence for Lithium's neuroprotective properties S-57-001 Barrat Luft, United Kingdom Peripheral inflammation in Bipolar Disorder (BP): Trait and state related alterations S-55-003 Klaus Munkholm, Denmark What is the risk for end stage renal disease with Lithium: A sophisticated review S-57-002 Ursula Werneke, Sweden Targeting mitochondrial inflammation in Bipolar Disorder M. Ott, E. Salander Renberg, B. Stegmayr (BP) Ana Andreazza, Canada S-55-004 An update on assessing and managing Lithium's renal S-57-003 effects Relationships between inflammation, elevated body Jonathan Meyer, USA mass index, and depressive relapse in Bipolar Disorder (BP) David Bond, USA

31 WFSBP 2017 THU

Preliminary Scientific Programme /Symposia

S-57-004 S-59-002 Genetic and central nervous system aspects of immune Neuregulin1-ErbB4 signaling: Integration at the network dysregulation in Bipolar Disorder (BP) level Bartholomeus Haarman, The Netherlands Beatriz Rico, United Kingdom S-59-003 T51: NEURODEGENERATIVE DISORDERS The relevance of Neuregulin1-ErbB4: Insights from mouse physiological analyses S-58 Andrés Buonanno, USA 08:30 – 10:00 Novel therapeutics for neurodegenerative disorders S-59-004 Neuregulin1-ErbB4 signaling: Insights from mouse Chair: Ramon Cacabelos García, Spain genetics S-58-001 Markus Schwab, Germany ASS234, as a new multi-target directed propargylamine for Alzheimer's Disease (AD) therapy T22: MOLECULAR NEUROBIOLOGY José Marco-Contelles, Spain S-60 S-58-002 08:30 – 10:00 EB101 immunotherapy against amyloid: A promising Multi-omics and psychiatry: The missing molecular link strategy for treating Alzheimer's Disease (AD) Ivan Carrera, Spain Chair: Michaela Filiou, Germany Co-Chair: Anthony Zannas, Germany S-58-003 The Intelligent Pharmacogenetic Card (PGx-iCard) for S-60-001 neuropsychiatric disorders Epigenomics of stress-related disorders: Current Juan C. Carril, Spain evidence, limitations, and future directions S-58-004 Anthony Zannas, Germany Neuroprotective effects of Atremorine in Cerebral Isch- S-60-002 emia and Parkinson disease-related models From proteomics to biological mechanisms involved in Javier Egea, Spain schizophrenia S-58-005 Daniel Martins de Souza, Brazil Basic and clinical studies with E-PodoFavalin-15999 S-60-003 (Atremorine®) in Parkinson's Disease: Selective dopami- Multi-omics driven discovery of pharmacological targets nergic neuroprotection and pharmacogenetics for stress-related disorders Ramon Cacabelos, Spain Michaela Filiou, Germany S-60-004 T22: MOLECULAR NEUROBIOLOGY Role of CYP2C19 in major depressive disorder – translational study S-59 Marin Jukic, Sweden 08:30 – 10:00 The relevance of Neuregulin1-ErbB4 signaling for T49: SUICIDE: BASIC / CLINICAL neuropsychiatric pathomechanisms: Converging insights from mouse genetics, physiology, and human S-61 studies 08:30 – 10:00 Chair: Peter Falkai, Germany Suicide: Aspects that burn Co-Chair: Moritz Rossner, Germany Chair: Konstantinos Fountoulakis, Greece S-59-001 Co-Chair: Dina Popovic, Spain The relevance of Neuregulin1-ErbB4 signaling for neu- S-61-001 ropsychiatric pathomechanisms: Insights from human Genetic basis of suicidal behaviour studies Alessandro Serretti, Italy Cyndi Shannon Weickert, Australia S-61-002 Mixed features and suicidality: Is DSM 5 wrong? Dina Popovic, Spain

32 THU WFSBP 2017

Symposia / Preliminary Scientific Programme

S-61-003 S-63-003 How does clinical prediction of suicidality affect our The endocannabinoid and endovanilloid system in daily clinical practice? stress-coping responses Mark Weiser, Israel Fabricio Moreira, Brazil M. Davidson S-63-004 S-61-004 Neurotrophins and psychiatric disorders Suicidality and overlaping geographical maps: Spuri- Eero Castrén, Finland ous correlations or cues for an underlying biological substrate? T43: SCHIZOPHRENIA: BASIC / CLINICAL Konstantinos Fountoulakis, Greece S-64 T49: SUICIDE: BASIC / CLINICAL 11:00 – 12:30 Operationalizing the dysconnection syndrome: S-62 Translational approaches reveal brain network 11:00 – 12:30 dysfunction in schizophrenia Innovative approaches in suicide research Chair: Bernat Kocsis, USA Chair: Philippe Courtet, France Co-Chair: Vaibhav Diwadkar, USA Co-Chair: Sidney Kennedy, Canada S-64-001 S-62-001 Dysconnection in rodent models of schizophrenia: Initiative for research network Directed connectivity analyses of frequency-tagged Sidney Kennedy, Canada oscillatory coupling of frontal-hippocampal signals S-62-002 Bernat Kocsis, USA Neurosciences based phenomenology of suicidal S-64-002 behaviour Ketamine disrupts the functional state of corticotha- Philippe Courtet, France lamic systems: A mechanistic model of first-episode S-62-003 psychosis MeMind project: Ambulatory assessment in suicide Didier Pinault, France behaviour. Do different things to expect different results? S-64-003 Enrique Baca Garcia, Spain Structural and functional brain dysconnectivity predat- S-62-004 ing the onset of psychosis The use of machine learning and big data to predict Stefan Borgwardt, Switzerland suicide S-64-004 Michael Berk, Australia The dynamics of the functional “dysconnectome” in schizophrenia: Network modeling of in vivo fMRI signals T33: PHARMACOLOGY Vaibhav Diwadkar, USA S-63 T24: NEUROPATHOLOGY 11:00 – 12:30 Atypical neurotransmitters in psychiatry: Relevance for S-65 future therapeutics 11:00 – 12:30 Chair: Gregers Wegener, Denmark Cell-type specific epigenetic, proteomic and gene Co-Chair: Sâmia Joca, Brazil expression signatures in schizophrenia: New findings from post-mortem investigations S-63-001 Chair: Peter Falkai, Germany Nitric oxide signalling in psychiatric disorders: Evidence Co-Chair: Andrea Schmitt, Germany from Gene x Environment x Development (GxExD) studies S-65-001 Gregers Wegener, Denmark Alteration of genome-wide gene expression in hippo- S-63-002 campal CA4 pyramidal neurons in schizophrenia ATP and NO interaction in stress models of depression Andrea Schmitt, Germany Sâmia Joca, Brazil

33 WFSBP 2017 THU

Preliminary Scientific Programme /Symposia

S-65-002 S-67-002 Is the energy dysfunction observed in schizophrenia Bipolar mixed states: Review of clinical presentation, brains being originated in oligodendrocytes? treatment and outcomes Daniel Martins de Souza, Brazil Mark Frye, USA S-65-003 S-67-003 Integrated analysis of cell-type specific epigenome-wide Major depressive disorder with mixed features: Epidemi- methylation changes in schizophrenia brains ology, clinical characteristics and prognosis Theo Kraus, Germany Allan Young, United Kingdom A. Schmitt, J. Spanner, P. Falkai, A. Giese S-67-004 S-65-004 Major depressive disorder with mixed features: Review Epigenetic signatures in the brain of schizophrenia of current treatment options patients Trisha Suppes, USA Andre Fischer, Germany T25: NEUROIMAGING: GENETIC, FUNCTIONAL, T33: PHARMACOLOGY STRUCTURAL S-66 S-68 11:00 – 12:30 15:00 – 16:30 NMDA receptor antagonists in psychiatry Dynamical brain: How brain complexity changes with Chair: Peter Gass, Germany aging and mental illness? Co-Chair: Gerard Sanacora, USA Chair: Chih-Chieh Yang, USA

S-66-001 S-68-001 Glutamatergic mechanisms in schizophrenia: Focus on Dynamical analysis of brain activity: A new research genetics dimension Dan Rujescu, Germany Chih-Chieh Yang, USA S-66-002 S-68-002 Insight into Ketamine's effect via cross-species transla- Assessment of neurophysiological changes with electro- tional neuroimaging convulsive therapy in mental disorders using nonlinear Oliver Grimm, Switzerland approach Ryoko Okazaki, Japan S-66-003 Molecular and cellular determinants of the pleiotropic S-68-003 effects of NMDA receptor antagonists Increasing signal variability during development and its Dragos Inta, Germany relevance to autism spectrum disorders Tetsuya Takahashi, Japan S-66-004 Antidepressant effects of NMDA receptor targeting S-68-004 drugs Neurophysiological basis of creativity in healthy elderly Gerard Sanacora, USA people using nonlinear approach Kanji Ueno, Japan T11: DEPRESSION: BASIC / CLINICAL S-67 11:00 – 12:30 Spectrum of Mood Disorders (MD): Where is the place for mixed states? Chair: Trisha Suppes, USA

S-67-001 Mood Disorders (MD) and mixed states: Evolution in diagnostic classification Roger McIntyre, Canada

34 THU WFSBP 2017

Symposia / Preliminary Scientific Programme

T19: INFLAMMATION PSYCHIATRY T7: CHILDHOOD & ADOLESCENT DISORDERS: BASIC / CLINICAL S-69 15:00 – 16:30 S-71 Increased intestinal permeability and bacterial 15:00 – 16:30 translocation in neuro-psychiatric disorders Sex-specific neuroendocrinological findings in conduct Chair: Michael Maes, Australia disorder Co-Chair: Yolanda Sanz, Spain Chair: Sabine Herpertz, Germany Co-Chair: Christine Freitag, Germany S-69-001 Increased intestinal permeability and bacterial translo- S-71-001 cation in depression and chronic fatigue syndrome The brain oxytocin system in intermale and female Michael Maes, Thailand aggression in rodents Trynke DeJong, Germany S-69-002 I. Neumann Increased intestinal permeability and bacterial translocation in chronic stress animal models S-71-002 Javier Caso, Spain Sex-specific differences in oxytocin effects on the brain's salience circuit S-69-003 Ruth Schmitt, Germany Increased intestinal permeability and bacterial translocation in neurodevelopmental disorders S-71-003 Yolanda Sanz, Spain Sex-specific differences and the effects of puberty on emotional processing in adolescents with and without S-69-004 conduct disorder Increased intestinal permeability and bacterial translo- Kerstin Konrad, Germany cation in schizophrenia Emily Severance, USA S-71-004 The role of basal and reactive steroid hormones and T26: NEUROPHYSIOLOGY neuropeptides in female conduct disorder Christine Freitag, Germany S-70 A. Martinelli, K. Ackermann, A. Bernhard, FemNAT-CD 15:00 – 16:30 study team Current use of EEG-based techniques in psychiatry Chair: Martijn Arns, The Netherlands T6: BIPOLAR DISORDERS: BASIC / CLINICAL Co-Chair: Adam Wichniak, Poland S-72 S-70-001 15:00 – 16:30 Epilepsy spectrum disorders and episodic psychiatric Socio-demographic and clinical differences between symptoms Bipolar I and II Disorder (BP) and implications for Nash N. Boutros, USA treatment S-70-002 Chair: Carlo Altamura, Italy Results of the international multi-center iSPOT-A study Co-Chair: Bernardo Dell'Osso, Italy in ADHD: EEG predictors of treatment outcome to S-72-001 methylphenidate Bipolar I vs II Disorder (BP): Characterization of Martijn Arns, The Netherlands socio-demographic and clinical variables in Italian S-70-003 and American samples Did the No-Go P300 component help to predict relapse Bernardo Dell'Osso, Italy in recently detoxified alcoholic patients? S-72-002 Salvatore Campanella, Belgium Clinical implications of predominant polarity and S-70-004 polarity index in Bipolar Disorders (BP) Polysomnographic measures of sleep in psychiatry: Eduard Vieta, Spain Implications for diagnosis and treatment Adam Wichniak, Poland

35 WFSBP 2017 THU SUN

Preliminary Scientific Programme /Symposia, Workshops

S-72-003 Workshops Epidemiology and clinical correlates of suicide and suicide attempts in Bipolar Disorders (BP) aaSunday, 18 June 2017 Maurizio Pompili, Italy T51: NATIONAL INITIATIVES S-72-004 WS-01 Do we have evidence for differentiating pharmacological treatment of Bipolar I from Bipolar II Disorder (BP)? 08:30 – 10:00 Terence Ketter, USA Initiatives from the Spanish Society of Biological Psychiatry: From evidence to experience Chair: Miquel Bernardo, Spain T43: SCHIZOPHRENIA: BASIC / CLINICAL Co-Chair: Ana Gonzalez Pinto, Spain S-73 15:00 – 16:30 WS-01-001 Agitation consensus Neuropathologic implication of abnormal cortico- Eduard Vieta, Spain basal ganglia connectivity in schizophrenia hallucination and its models WS-01-002 Chair: Hiroyuki Nawa, Japan ECT consensus Mikel Urretavizcaya, Spain S-73-001 WS-01-003 Neuropathologic implication of pallidal hyperactivity Clinical guidelines for adult patients with a severe men- in the auditory abnormality of schizophrenia animal tal disorder and a comorbid substance use models Luis San, Spain Hiroyuki Nawa, Japan S-73-002 T7: CHILDHOOD & ADOLESCENT DISORDERS: The rat ketamine model of schizophrenia shows BASIC / CLINICAL aberrant oscillatory activity in the cortico-basal ganglia circuit WS-02 Miguel Valencia, Spain 10:15 – 11:45 S-73-003 New investigations on the relationship between Excess striatal dopamine and aberrant information working memory and ADHD processing model of psychosis in schizophrenia Chair: Joseph Biederman, USA Jong Yoon, USA WS-02-001 S-73-004 Clinical correlates of working memory deficits in youth Subcortical modulation in auditory processing and with and without ADHD auditory hallucinations Ronna Fried, USA Toshikazu Ikuta, USA WS-02-002 Are working memory deficits and ADHD sissociable?: An fMRI study Joseph Biederman, USA WS-02-003 Reduced prefrontal efficiency for visuospatial working memory in attention-deficit / hyperactivity disorder Jeffrey Newcorn, USA WS-02-004 Working memory deficits in a prenatal nicotine exposure mouse model Pradeep Bhide, USA

36 MON TUE WFSBP 2017

Workshops / Preliminary Scientific Programme

aaMonday, 19 June 2017 aaTuesday, 20 June 2017 T47: STIMULATION METHODS (ECT, TMS, VNS, DBS) T43: SCHIZOPHRENIA: BASIC / CLINICAL WS-03 WS-05 11:15 – 12:45 08:30 – 10:00 Current status of electroconvulsive therapy in the Gesture as window to psychosis pathobiology: From treatment of major psychiatric disorders aberrant body experience to social interaction Chair: Yong-Sik Kim, Republic of Korea Chair: Sebastian Walther, Switzerland Co-Chair: Pascal Sienaert, Belgium Co-Chair: Vijay Mittal, USA

WS-03-001 WS-05-001 Current status on efficacy of ECT Schizophrenia in the flesh: Empirical studies of anoma- Hans Mørch Jensen, Denmark lous bodily self experiences WS-03-002 So-Hee Park, USA Mechanism of ECT focused on psychosis WS-05-002 Ung-Gu Kang, Republic of Korea Impaired gesture performance in schizophrenia: Neuro- WS-03-003 biology and clinical consequences ECT for the treatment resistant psychosis Sebastian Walther, Switzerland In-Won Chung, Republic of Korea WS-05-003 WS-03-004 The neural correlates of natural social-communicative ECT in catatonia perception processes in patients with schizophrenia: Pascal Sienaert, Belgium Understanding, recognition and interpretation of verbal and non-verbal information Benjamin Straube, Germany T11: DEPRESSION: BASIC / CLINICAL WS-05-004 WS-04 What can gesture-speech mismatch tell us about patho- 15:00 – 16:30 physiology underlying psychosis-risk syndromes? Rethinking depression in the Century XXI: Where are Vijay Mittal, USA we now in biological psychiatry? Chair: Victoria Valdez, Argentina T49: SUICIDE: BASIC / CLINICAL Co-Chair: Adriana Rivetti, Argentina WS-06 WS-04-001 11:15 – 12:45 Is depression an inflamatory-metabolic disease? Neurobiology of suicidal behaviour Andrea Marquez Lopez Mato, Argentina Chair: Leo Sher, USA WS-04-002 Co-Chair: Zoltan Rihmer, Hungary Genetics risk variants for major depressive disorder Alejo Corrales, Argentina WS-06-001 Testosterone and suicidal behavior in men and women WS-04-003 Leo Sher, USA Rethinking depression in the Century XXI Victoria Valdez, Argentina WS-06-002 Suicide in men: Clinical and biological correlates WS-04-004 Zoltan Rihmer, Hungary Serotonergic hypothesis of depression: Is still up-to- date? WS-06-003 Adriana Rivetti, Argentina Neuroinflammatory biomarkers of suicidal behavior Jussi Jokinen, Sweden WS-06-004 Endophenotypes of suicidal behavior for genetic research Xenia Gonda, Hungary

37 WFSBP 2017 TUE WED

Preliminary Scientific Programme /Workshops

T11: DEPRESSION: BASIC / CLINICAL aaWednesday, 21 June 2017 WS-07 T43: SCHIZOPHRENIA: BASIC / CLINICAL 15:00 – 16:30 WS-09 Merging evidence and clinical practice in management 11:15 – 12:45 of depression: The CANMAT experience Schizophrenia research in Chile Chair: Sidney Kennedy, Canada Chair: Hernan Silva, Chile Co-Chair: Roumen Milev, Canada Co-Chair: Veronica Larach, Chile WS-07-001 WS-09-001 Guidelines for Pharmacological Management of BDNF as a biomarker of cognitive function in schizo- Depression phrenia: A study in Chilean population Raymond Lam, Canada Hernan Silva, Chile WS-07-002 WS-09-002 Making Effective Guidelines: Examples of Evidence- Pragmatic and linguistic disorders in schizophrenia based Dissemination and Implementation Strategies since the first episode Sagar Parikh, USA Eduardo Duran, Chile WS-07-003 WS-09-003 Guidelines for the treatment of depression in specific Atypical antipsychotics and psychosis spectrum: Chilean populations: making decisions despite gaps in evidence experience Glenda MacQueen, Canada Eugenio Olea, Chile WS-07-004 WS-09-004 Guidelines for the use of complementary and alternative Universal coverage for schizophrenia: The GES pro- medicines ( CAM ) in major depression gramme in Chile Arun Ravindran, Canada Veronica Larach, Chile

T51: NEUROPSYCHOPATHOLOGY T43: SCHIZOPHRENIA: BASIC / CLINICAL WS-08 WS-10 15:00 – 16:30 15:00 – 16:30 Functional neuroanatomy of hallucinations Evidence for brain stimulation methods in Chair: Rajesh Nagpal, India schizophrenia Co-Chair: Harishchandra Gambheera, Sri Lanka Chair: Joachim Cordes, Germany WS-08-001 Co-Chair: Christian Plewnia, Germany Functional neuroanatomy of auditory hallucinations WS-10-001 E. Mohandas Warrier, India Effects of transcranial direct current stimulation (tDCS) WS-08-002 on executive functions Neural signature of visual hallucinations Christian Plewnia, Germany Venu Gopal Jhanwar, India WS-10-002 WS-08-003 rTMS for the treatment of negative symptoms in residual Neural mechanisms of somatic, musical and extracamp- schizophrenia ine hallucinations Joachim Cordes, Germany Anukant Mital, India WS-10-003 WS-08-004 The treatment of hallucinations in schizophrenia spec- The neural signature overlap between delusions and trum disorders hallucinations Iris Sommer, The Netherlands Debashis Ray, India WS-10-004 Predictors of response to ECT in treatment-resistant schizophrenia Tomasz Pawelczyk, Poland

38 WFSBP 2017 Topics

The scientific programme of the WFSBP 2017 Congress will cover the following topics. Within each topic the track may be basic, clinical, interface or conceptual:

1. Addictive Disorders 26. Neurophysiology 2. Antidepressants: Basic / Clinical 27. Obsessive-Compulsive Disorders: Basic / Clinical 3. Antipsychotics: Basic / Clinical 28. Pain: Basic / Clinical 4. Anxiety Disorders: Basic / Clinical 29. Panic Disorders: Basic / Clinical 5. Anxiolytics: Basic / Clinical 30. Personality Disorders: Basic / Clinical 6. Bipolar Disorders: Basic / Clinical 31. Pharmacoeconomics 7. Childhood & Adolescent Disorders: Basic / Clinical 32. Pharmacogenetics 8. Chronobiology and Psychiatry 33. Pharmacology 9. Cognitive Neuroscience 34. Phototherapy 10. Dementia: Basic / Clinical 35. Posttraumatic Stress: Basic / Clinical 11. Depression: Basic / Clinical 36. Pregnancy, post partum and new born: Basic / Clinical 12. Eating Disorders: Basic / Clinical 37. Premenstrual Syndrome: Basic / Clinical 13. Emergency Psychiatry 38. Psychogeriatrics 14. Epidemiology 39. Psychoneuroimmunology 15. Ethics in Biological Psychiatry 40. Psychopathology 16. Forensic Psychiatry 41. Psychosurgery 17. Genetics 42. Psycho-Oncology 18. Hypnotics: Basic / Clinical 43. Schizophrenia: Basic / Clinical 19. Inflammation Psychiatry 44. Sexual Disorders: Basic / Clinical 20. Liaison Psychiatry 45. Sleep Disorders: Basic / Clinical 21. Mental Retardation or Chromosomal 46. Somatoform Disorders: Basic / Clinical Aberrations: Basic / Clinical 47. Stimulation Methods (ECT, TMS, VNS, DBS) 22. Molecular Neurobiology 48. Stress: Basic / Clinical 23. Mood Stabilisers: Basic / Clinical 49. Suicide: Basic / Clinical 24. Neuropathology 50. Violence: Basic / Clinical 25. Neuroimaging: Genetic, Functional, Structural 51. Miscellaneous

Copenhagen, Nyhavn harbor @ tanya / fotolia.com 39 WFSBP 2017 Call for Abstracts for Free Communications and Posters

Deadline for abstract submission: 6 December 2016 GUIDELINES FOR THE PREPARATION OF ABSTRACTS Notification of acceptance / rejection: Early March 2017 Please submit your abstracts online and in English, the official language of the WFSBP Congress 2017. Authors of Free Communications or Posters are hereby kindly invited to submit an abstract for contributions to the aaPlease choose a title that clearly indicates the content of WSFBP 2017 Congress by using the online submission the contribution. form on the congress website www.wfsbp-congress.org. aaPlease avoid abbreviations in the title. Abbreviations Please note that online submission is mandatory. may be used in the text if they are defined when used Free Communications and Posters submitted individually first. and accepted by the International Scientific Programme aaThe author’s name (full first name, family name) and Committee will be grouped by category topics into the- place of work (institution, city, country) should be matic sessions in order to promote communication given. Degrees, titles, street addresses, and acknowledg- among the presenters and participants and to allow for ments of support should be omitted, however. inspiring discussions. aaThe abstract submission must be complete. aaPlease choose a topic from the topic list. FREE COMMUNICATIONS aaThe text of the abstract should briefly state: Objectives Free Communications will be selected by the International (indicate the purpose of the study or the hypothesis that Scientific Programme Committee after abstract submis- was tested), Methods (include the setting for the study, sions have been reviewed. The 90-minute sessions will be the subjects, the diagnosis or intervention, and the type grouped by topics and chaired by selected specialists. The of statistical analysis. If references are needed, they time slot for a single presentation in a Free Communica- should be given in the text), Results (present as clearly tion session is 15 minutes including discussion time. Only as possible the outcome of the study and statistical 1 Free Communication abstract may be submitted per significance if appropriate) and Conclusions (briefly dis- author. cuss the data and emphasize the significance of the results). References need to be given in the text. POSTERS aaThe length of your abstract is limited to a maximum of Each accepted poster will be exhibited at the WFSBP 300 words. 2017 Copenhagen Congress at the Bella Center. The best aaPlease ensure that the abstract does not contain spell- posters will be grouped into thematic Guided Poster Tours ing, grammar or scientific errors, as it will be repro- chaired by renowned specialists. The Guided Poster Tours duced exactly as submitted. Submitted abstracts will not will give authors the opportunity to present their findings be edited in any way. If the abstract does not fulfill the and discuss them with the audience. necessary requirements it cannot be published. A maximum of 4 posters abstracts may be submitted per aaA disclosure of the existence of any significant financial author. The congress will deliver WFSBP Young Investiga- interest or other affiliations with a funding organisation tor Awards for the five best posters. Please refer to page 43 or with a commercial supporter of the session and / or for further information. provider of commercial services is required. aaAll abstracts will be published online in the scientific Please note that accepted abstracts will be published only programme of the WFSBP Congress from April 2017. after completed registration and payment of the congress aaOnly 1 Free Communication Abstract / Young Scientist registration fee. The acceptance of submitted abstracts Award Abstract may be submitted per author. simultaneously results in binding registration of the speak- aaA maximum of 4 posters may be submitted by each er to attend the conference. The registration fee must be author. paid immediately after receiving the abstract acceptance, at the latest until 20 March 2017. Authors who have not settled the registration fee until that date will be omitted from the scientific programme. Onsite registration for presenting authors is not possible.

40 WFSBP 2017

Submission Procedure For any further assistance, please contact the congress and Abstracts for Free Communications, Young Scientist exhibition offi ce: Awards and Posters have to be submitted electronically by using the online form on the congress website www. wfsbp-congress.org. Phone: +49 – 30 – 300 669-0 Detailed instructions regarding the electronic submission Email: [email protected] procedure can be found on the website.

We organize your success

CPO HANSER SERVICE is specialized in the ﬁ eld of Conference, Event, Destination Management and, ssociation Management and has been organizing events of any size throughout Germany and worldwide for more than 35 years.

CONFERENCE – EVENT – DESTINATION – ASSOCIATION MANAGEMENT

We offer you:

n the best congress organization BERLIN n state-of-the-art online solutions Paulsborner Str. 44 n electronic abstract handling 14193 Berlin, Germany phone +49-30-300 669 0 n CME accreditation handling fax +49-30-305 73 91 n effective congress technology email [email protected] n sponsoring and exhibition acquisition and management HAMBURG n ﬁ nance management Zum Ehrenhain 34 n professional tax solutions 22885 Barsbüttel, Germany phone +49-40-670 882 0 n creative event programs fax +49-40-670 32 83 n inhouse graphic design email [email protected]

www.cpo-hanser.de

41 WFSBP 2017 Format Descriptions of the Scientific Sessions

OPENING LECTURE WORKSHOPS The Opening Lecture will be held during the Opening Workshops are 90-minute highly interactive sessions with Ceremony on 18 June 2017. an educational focus. This format is designed to give specific regions a platform for presentation and networking. PLENARY LECTURES Plenary Lectures are 45-minute sessions held by renowned FREE COMMUNICATIONS experts. The speakers have been chosen among the most Authors are invited to submit abstracts on their latest prominent researchers in the respective field. research findings. All submitted abstracts will be reviewed and the best will be selected and allocated to Free Com- DEBATES munication Sessions. Debates are intended to offer a platform for a lively, yet balanced discussion on controversial issues. A moderator GUIDED POSTER TOURS (chairperson) and two speakers (one proponent and one Abstracts on new research findings and/or major research opponent) will state their opinions on different subjects. efforts are expected to be submitted for the poster category. For those abstracts which will be submitted by young WFSBP TASK FORCE SYMPOSIA investigators for the poster category, the Local Organising A good number of WSFBP Task Forces have submitted Committee will arrange Guided Poster Tours to give the Symposia organised by their key members on issues relat- authors the opportunity to present these findings and dis- ed to their field of special expertise. All of them have been cuss them with the audience. included in the scientific programme and pertain to Treat- ment Guidelines, Consensus Statements and other hot EDUCATIONAL GRANT SESSIONS topics in their respective thematic areas. (Young Scientists Award Sessions) These sessions are dedicated to young researchers up to WFSBP TASK FORCE WORKSHOPS 40 years of age which will be pre-selected via an applica- A good number of WSFBP Task Forces have submitted tion process. Herewith the WFSBP is promoting education Workshops organised by their key members on issues re- for talented young researchers. Interactional and practical lated to their field of special expertise. All of them have learning is in the focus of these sessions. The educational been included in the scientific programme and pertain to grant sessions are open to all congress delegates. Treatment Guidelines, Consensus Statements and other hot topics in their respective thematic areas. INDUSTRY SPONSORED SYMPOSIA These 60- to 90-minute sessions are fully integrated into SYMPOSIA the congress. The sessions are organised and executed by Symposia are selected, covering basic, clinical, interface, the pharmaceutical industry by unrestricted educational and conceptual topics of Biological Psychiatry. Symposia grants. are 90-minute sessions and will be organised and chaired by the experts whose proposals are accepted by the Inter- CME ACCREDITATION national Scientific Programme Committee. An application will be made to the EACCME® for CME accreditation of this event.

42 WFSBP 2017 WFSBP Awards

The following WFSBP Awards will be delivered and pre- aaWFSBP Young Investigator Awards for the five best sented during the 13th World Congress of Biological Psy- posters (under 40 year-old) chiatry 2017 in Copenhagen. An application for the Young Investigator Award is not necessary. All posters will be evaluated at the congress. aaWFSBP Lifetime Achievement Award in Biological The awards will go to those presentations that not only Psychiatry provide evidence of innovative research, but which are The WFSBP Lifetime Achievement Award in Biological also well presented. Psychiatry is intended for senior research scientists (MD, PhD or equivalent) whose lifework has significantly in- Please note that presenting authors must register and fluenced today‘s field of biological psychiatry. This attend the meeting to be eligible for any of these awards. award is open to members and non-members of the WFSBP. It consists of a monetary award of EUR 1,000. Applications must be sent by e-mail to the congress and exhibition office: aaWFSBP Award for Scientific Excellence of the WFSBP Host The WFSBP Award for Scientific Excellence of the Phone: +49 – 30 – 300 669-0 WFSBP Host is dedicated to an outstanding researcher Email: [email protected] in the field of Biological Psychiatry originating from the host country of the World Congress of Biological by 6 December 2016 and should include a short summary Psychiatry. This award consists of a monetary award of of the work and a brief CV. The letter should outline the EUR 1,000. main professional activities and provide key peer review publications. Prizes will be announced during the Open- aaWFSBP Research Prize ing Ceremony. Poster prizes will be delivered during the The WFSBP Research Prize is intended for WFSBP Closing Ceremony. members (MD, PhD or equivalent) whose current scientific work has had an important impact in the field of clinical and / or basic research in the area of biological psychiatry. This prize consists of a monetary award of EUR 1,000. aaWFSBP Award for Excellence in Education The WFSBP Award for Excellence in Education is to ac- knowledge outstanding and innovative education in biological psychiatry including the implementation of new interactive media. The WFSBP Education prize is open to all WFSBP members who have improved the education in all fields of Psychiatry. This award consists of a monetary award of EUR 1,000.

43 WFSBP 2017 Congress Information

Congress Registration for the 13th World Congress of Biological Psychiatry is available via the congress website at www.wfsbp-congress.org.

Registration and Early registration Late registration On-site registration payment received by 25 January 2017 by 31 May 2017 after 31 May 2017 EUR EUR EUR WFSBP Members 530 630 730 Non-Members 630 730 830 Participants from Low-Income Countries* 290 390 490 Trainees** 290 390 490

* According to the Low-Income-Countries defined by the world bank. Please see the list on the WFSBP website www.wfsbp-congress.org ** Trainee / Student status must be confirmed by certificate in writing by head of department and is applicable only for participants born after 1 Jan 1982. Please send your certificate by email or fax to: CPO HANSER SERVICE GmbH, Fax: +49 – 30 –305 73 91, Email: [email protected]

PAYMENT CONFIRMATION When registering for the WFSBP 2017 Congress in Co- Upon receipt of the registration and the corresponding penhagen, please arrange for payment of the registration payment, the congress office will send a confirmation fee. All payments should be made in EURO. You may form which also serves as an invoice. Please show this choose between two modes of payment: credit card pay- confirmation of registration at the congress counter when ment or bank transfer. Especially for payment made from picking up your congress materials. outside Germany where the congress office is based, we strongly recommend credit card payments as charges for CANCELLATION OF CONGRESS PARTICIPATION bank transfers may apply twice, once in the country of Notice of cancellation should be sent in writing only to origin and a second time in Germany. the Congress Office CPO HANSER SERVICE. In case of cancellation by 25 January 2017 the payment will be re- Please choose one mode of payment: funded, minus a handling charge of 25%. No refund will Credit card: AMEX, Mastercard or VISA be made after 25 January 2017. or bank transfer to the congress bank account: Hanser & Co GmbH w / WFSBP 2017 ZB ON-SITE REGISTRATION AFTER 31 MAY 2017 Deutsche Bank Privat- u. Geschäftskunden AG, Berlin / On-site registration will be possible but we recommend to Bank Code: 1007 0024 register well in advance. Participants who wish to register Account Number: 108 96 97 02 on-site are advised to arrive early. On-site registration does BIC: DEUT DE DB BER not entitle participants to receive a delegate bag. On-site IBAN: DE 45 1007 0024 0108 9697 02 registration will be handled on a first-come, first-served basis, priority will be given to pre-registered delegates.

44 WFSBP 2017 General Information

CONGRESS VENUE TECHNICAL EXHIBITION Bella Center Copenhagen The WFSBP Congress 2017 will be accompanied by a Center Boulevard 5 major technical exhibition taking place in Hall A 1 of the 2300 Copenhagen S, Denmark Bella Center. Potential exhibitors can request an exhibi- Entrance: Congress Foyer tion / sponsoring brochure from the exhibition office CPO HANSER SERVICE. CONGRESS REGISTRATION DESK Email: [email protected] The congress counter will be located in the Foyer. Preliminary opening hours Preliminary opening hours Monday, 19 June 2017 09:00 – 17:00 Saturday, 17 June 2017 16:00 – 19:00 Tuesday, 20 June 2017 09:00 – 17:00 Sunday, 18 June 2017 07:30 – 19:00 Wednesday, 21 June 2017 09:00 – 17:00 Monday, 19 June 2017 08:00 – 18:30 Tuesday, 20 June 2017 08:00 – 18:30 CONGRESS INFORMATION SYSTEM / Wednesday, 21 June 2017 08:00 – 18:30 CO CONGRESS ONLINE® Thursday, 22 June 2017 08:00 – 17:30 The web based Congress Information System CO CON- GRESS ONLINE® has been installed at CONGRESS AND EXHIBITION OFFICE www.wfsbp-congress.org

Prior to the congress, CO CONGRESS ONLINE® will provide information on: Phone: +49 – 30 – 300 669-0 aaPreparation of the congress Email: [email protected] aaList of topics aaCall for abstracts POSTER EXHIBITION aaInvited speakers and invited conveners of symposia Posters will be displayed from Monday, 19 June to Thurs- aaPreliminary scientific programme day, 22 June 2017 in Hall A 1 next to the technical exhibi- aaAccepted abstracts tion. Each congress day there will be one Guided Poster aaList of exhibitors Tour with the best posters only. The posters selected for the aaInformation about the main sponsors Guided Poster Tour will be displayed in a special area of aaCopenhagen the congress center. During the review of the abstracts aaHotel accommodation which is done by the Local Organising Committee, the re- aaTravel to Copenhagen viewers will indicate the candidates for the Guided Poster aaSpecial news Tours. All other posters will be displayed for one entire aaPrivate mailbox congress day and grouped according to topics. In due time, the final programme will be published on Information regarding poster format, set-up and disman- CO CONGRESS ONLINE® which enables each participant tling will be sent to the authors along with their notifica- to create her / his personal congress programme schedule. tion of acceptance. CO CONGRESS ONLINE® offers an extensive congress service.

45 WFSBP 2017 General Information

FINAL PROGRAMME INSURANCE The final programme and abstracts will be published Please note that the congress fee does not include insur- on the Internet at www.wfsbp-congress.org prior to the ance. All participants should arrange for their own insur- congress. ance. Health and accident insurance is strongly recom- mended and will need to be purchased in the country of WFSBP 2017 CONGRESS APP MOBILE origin. The WFSBP 2017 Congress App is free for congress participants and provides iPhone / iPad and android smartphone FORCE MAJEURE users at WFSBP 2017 in Copenhagen with on-the-go For reasons beyond its control (such as war, strikes, lock- access to the congress. The most up-to-date congress outs, riots or any such civil disturbances, any natural disas- schedule is available at the fingertips during the congress. ter, including but not limited to earthquakes, floods, droughts and typhoons and any other cause of circum- CONGRESS LANGUAGE stance of whatsoever nature beyond control) that have an The official language of the WFSBP Congress 2017 is impact on the arrangements, timetables or planning of the English. Simultaneous translation will not be provided. 13th World Congress of Biological Psychiatry (WFSBP 2017) and its corresponding activities in Copenhagen, WFSBP LETTER OF INVITATION has the right to immediately alter or cancel the activities or The congress will be pleased to send a formal letter of in- events or any of the arrangements, timetables, plans or oth- vitation to any registered delegate requesting one. It is un- er items relating directly or indirectly thereto. No party in- derstood that such an invitation is intended to help poten- volved shall be entitled to any compensation for damages tial delegates to raise funds or to obtain a visa. This does that result from such alteration or cancellation. not imply a commitment from the congress to provide any financial support. Letters of invitation may be requested CURRENCY from the congress office. The Danish currency is the Danish Krone (DKK). The Dan- ish Krone is pegged to the Euro and convertible on world VISA currency markets. The exchange rate fluctuates daily de- The entry formalities for Denmark vary according to the pending on the money market. country of origin. The Ministry of Foreign Affairs of Den- www.oanda.com mark provides a list of countries that require a visa to enter the country. Please visit the website http:// um.dk/en. CLIMATE Copenhagen is in the oceanic climate zone. Summer OFFICIAL ITALIAN AGENCY months are moderately warm and quite pleasant. June is For Italian delegates only: the sunniest month of the year with an average of about Any Italian pharmaceutical company supporting or partic- eight hours of sunshine a day and the temperature varies ipating in a congress abroad, is subjected to an authoriza- between 11°c (52 °F) and 19°c (66°F). tion by AIFA (Italian Drug Agency), according to an Italian Government Decree (Decreto Legislativo 219 / 06 – art. TRAVEL TO COPENHAGEN AND BELLA CENTER 124). The request of authorization must be submitted By plane Copenhagen is easy accessible from many Euro- within 60 days before the starting date of the event. The pean airports with direct flight connections. It is the larg- appointed agency to collect all applications from pharma- est airport in Scandinavia. From Copenhagen Airport it ceutical companies and file them with the AIFA is: takes 10 minutes to reach the Bella Center. A regional train runs from the airport to Ørestad Station, the train AIM Group International – AIM Education S.r.l. station of the Bella Center. Valentina Disabato / Cristina Ghidoli By train Copenhagen Central Station is located in the heart Via G. Ripamonti, 129 l 20141 Milan, Italy of the city, bordering to the rough but also trendy Vesterbro. Phone: +39 – 02 – 56601.288/360 It is a gateway to all public transportation in and out and Fax: +39 – 02 – 70048585 around Copenhagen. From Copenhagen Central Station it Email: [email protected] takes approx. 10 minutes by metro to reach the Bella Cen- www.aimgroupinternational.com ter. The name of the metro station is also Bella Center.

46 WFSBP 2017 General Information

By car Bella Center is located at Center Boulevard 5, 2300 CITY OF COPENHAGEN Copenhagen S. Follow the „Airport Motorway“, E20. The Copenhagen is not only the capital of Denmark. It is a cul- exit to Center Boulevard is number 19 and is called tural and economic center of Northern Europe. More than „Ørestad“ with „Bella Center“ listed below. 1,2 million citizens live in the greater Copenhagen region.

PUBLIC TRANSPORTATION IN COPENHAGEN The city is located on the Danish Island „Saeland“ (Dan- Public transportation in Copenhagen is reliable, punctual, ish: Sjælland) and next to the „Øresund“ – a Baltic sea and it goes everywhere in the city. In Copenhagen the seagate and natural borderline to Sweden. Due to this trains, metro and busses (including waterbuses) can be ac- geographic location, Copenhagen – together with the cessed with the same ticket. All you need to know is how Swedish city Malmö – represents the binational „Øresund many zones you will pass on your journey. Note the met- Region“. It is a unique metropolis area, where two coun- ro will take you from the airport to central Copenhagen in tries and cities are connected via the 8 km „Øresund only 13 minutes. Bridge“.

TAXIS TO BELLA CENTER The Copenhagen Palaces Christiansborg and Amalien- Bella Center is just a 10 – 15 minute taxi drive from Copen- borg are the seat of the Danish Parliament and the resi- hagen Central Station and not more than 10 minutes from dence of the Danish Queen Margrethe II. Architecture, Copenhagen Airport by taxi. A taxi from Bella Center to the design and music make Copenhagen an outstanding cul- city centre costs about DKK 200-250. A taxi from Bella tural hotspot in Northern Europe. It is famous for its in- Center to Copenhagen Airport costs about DKK 150-200. novative improvements which can be seen and experi- enced throughout the city.

Also, Copenhagen has great museums to offer, for exam- ple Louisiana and The National Gallery of Denmark. The Royal Danish Opera, located directly at the habor front, is combining modern Danish architecture with international performances. The main sightseeing spots and touristic attractions are the Tivoli Gardens, Christiansborg, and of course the „Little Mermaid“ – the famos sculpture of Edvard Eriksen at the waterside.

The University of Copenhagen is offering a wide range of academic disciplines. With over 40,000 students and © Chefsamba / Fotolia.com more than 9,000 employees, the University of Copenha- HOTELS IN COPENHAGEN gen is one of the largest institutions of research and edu- CPO HANSER SERVICE GmbH has reserved a large num- cation in the Nordic countries. ber of hotel rooms in various hotels in different price cat- egories in Copenhagen. The majority of the hotel rooms Due to short distances within the city of Copenhagen, its are located close to Bella Center. good public transportation system, and especially the well Reservations will be possible via CO HotelOnline® on the developed cycle paths, Copenhagen is a convenient place website www.wfsbp-congress.org. Bookings by email or for meetings. telephone cannot be accepted.

CPO HANSER SERVICE

Phone: +49 – 30 – 300 669-0 Email: [email protected]

47 Dates to remember

6 December 2016 Deadline for abstract submission for free communications and posters

25 January 2017 Deadline early bird registration

31 May 2017 Deadline late registration

18 June 20157 Opening Ceremony and Networking Reception